Official Title:    Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by  
Open-label Inclisiran [Year 2]) Randomized Multicenter Study 
to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in 
Adolescents (12 to Less Than 18 Years) With Heterozygous 
Familial Hypercholesterolemia and Elevated LDL-cholesterol 
(ORION-16)
Study ID: [REMOVED]  
Document Date: Clinic al Study Protocol (Amendment 2): 17-Feb-2023
Novartis Research and Development  
KJX839/inclisiran 
Clinical Trial Protocol CKJX839C12301  
Two part (double -blind inclisira n versu s placeb o [Ye ar 1] 
followe d by open-labe l inclisira n [Year 2]) randomized 
multicente r stud y to evaluat e safety, tolerability, and 
efficac y of inclisira n in adolescent s (12 to l ess tha n 18 
years) with h eterozygous familial h ypercholesterolemia 
and elevate d LDL -choleste rol (OR ION-1 6) 
Document type:  Amended  Protocol  Version  
EUDRACT number:  2020 -002757 -18 
Version number:  02 (Clean ) 
Clinical Trial Phase:  III 
Release date:  17-Feb-2023  (Content Final)
Property of Novartis  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of Novartis  
Clinical Trial Protocol Template Version 3.0 dated 31 -Jan-2020  
Novartis  Confidential  Page 2 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Table of contents  
Table of contents ................................................................................................................. 2 
List of tables  ........................................................................................................................ 5 
List of figures  ...................................................................................................................... 6 
List of abbreviations  ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 10 
Amendment 2 (17- Feb-2023) ................................................................................................... 12 
Amendment 1 (28- Oct-2022) ................................................................................................... 13 
Protocol summary  .............................................................................................................. 16 
1 Introduction ....................................................................................................................... 18 
1.1 Background ............................................................................................................ 18 
1.2 Purpose .................................................................................................................. 20 
2 Objectives and endpoints ................................................................................................... 20 
2.1 Primary estimands  ................................................................................................. 21 
2.2 Secondary estimands ............................................................................................. 22 
3 Study design ...................................................................................................................... 22 
4 Rationale ............................................................................................................................ 24 
4.1 Rationale for study design ..................................................................................... 24 
4.1.1 Rationale for choice of background therapy ......................................... 25 
4.2 Rationale for dose/regimen and duration of treatment .......................................... 25 
4.3 Rationale for choice of control drugs (comparator/placebo)  ................................. 26 
4.4 Purpose and timing of interim analyses/design adaptations .................................. 26 
4.5 Risks and benefits .................................................................................................. 27 
5 Study Population ............................................................................................................... 28 
5.1 Inclusion criteria  .................................................................................................... 28 
5.2 Exclusion criteria  ................................................................................................... 29 
6 Treatment  ........................................................................................................................... 30 
6.1 Study treatment ...................................................................................................... 30 
6.1.1 Investigational and control drugs .......................................................... 30 
6.1.2 Additional study treatments .................................................................. 31 
6.1.3 Treatment arms/group  ........................................................................... 31 
6.1.4 Treatment duration  ................................................................................ 32 
6.2 Other treatment(s)  .................................................................................................. 32 
6.2.1 Concomitant therapy  ............................................................................. 32 
6.2.2 Prohibited medication  ........................................................................... 33 
6.3 Participant numbering, treatment assignment, randomization  .............................. 34 
6.3.1 Participant numbering  ........................................................................... 34 
Novartis  Confidential  Page 3 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
6.3.2 Treatment assignment, randomization  .................................................. 34 
6.4 Treatment blinding  ................................................................................................ 34 
6.5 Dose escalation and dose modification .................................................................. 35 
6.5.1 Dose modifications ................................................................................ 35 
6.5.2 Follow-up for toxicities ......................................................................... 36 
6.6 Additional treatment guidance ............................................................................... 38 
6.6.1 Treatment compliance  ........................................................................... 38 
6.6.2 Recommended treatment of adverse events  .......................................... 38 
6.6.3 Emergency breaking of assigned treatment code  .................................. 38 
6.7 Preparation and dispensation  ................................................................................. 39 
6.7.1 Handling of study treatment and additional treatment .......................... 39 
6.7.2 Instruction for prescribing and taking study treatment ......................... 39 
7 Informed consent procedures ............................................................................................ 40 
8 Visit schedule and assessments  ......................................................................................... 41 
8.1 Screening  ............................................................................................................... 47 
8.1.1 Information to be collected on screening failures ................................. 47 
8.2 Participant demographics/other baseline characteristics  ....................................... 47 
8.3 Efficacy  .................................................................................................................. 47 
8.3.1 LDL -cholesterol  .................................................................................... 48 
8.3.2 Other efficacy biomarkers  ..................................................................... 48 
  48 
8.3.4 Appropriateness of efficacy assessments  .............................................. 48 
8.4 Safety  ..................................................................................................................... 48 
8.4.1 Laboratory evaluations  .......................................................................... 49 
8.4.2 Electrocardiogram (ECG) ..................................................................... 50 
8.4.3 Pregnancy .............................................................................................. 51 
8.4.4 Other safety evaluations  ........................................................................ 51 
8.4.5 Appropriateness of safety measurements  .............................................. 53 
8.5 Additional assessments  .......................................................................................... 53 
  53 
8.5.2 Biomarkers  ............................................................................................ 53 
  53 
9 Study discontinuation and completion .............................................................................. 54 
9.1 Discontinuation and completion ............................................................................ 54 
9.1.1 Study treatment discontinuation and study discontinuation.................. 54 
9.1.2 Withdrawal of informed consent  ........................................................... 55 
9.1.3 Lost to follow -up ................................................................................... 56 

Novartis  Confidential  Page 4 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
9.1.4 Early study termination by the sponsor ................................................. 56 
9.2 Study completion and post- study treatment  .......................................................... 57 
10 Safety monitoring and reporting  ........................................................................................ 57 
10.1 Definition of adverse events and reporting requirements ...................................... 57 
10.1.1 Adverse events ...................................................................................... 57 
10.1.2 Serious adverse events  .......................................................................... 58 
10.1.3 SAE reporting........................................................................................ 59 
10.1.4 Pregnancy reporting .............................................................................. 60 
10.1.5 Reporting of study treatment errors including misuse/abuse ................ 61 
10.2 Additional Safety Monitoring  ................................................................................ 61 
10.2.1 Liver safety monitoring  ......................................................................... 61 
10.2.2 Renal safety monitoring  ........................................................................ 62 
10.2.3 Other safety monitoring  ........................................................................ 62 
10.2.4 Data Monitoring Committee  ................................................................. 62 
10.2.5 Steering Committee  ............................................................................... 63 
11 Data Collection and Database management  ...................................................................... 63 
11.1 Data collection  ....................................................................................................... 63 
11.2 Database management and quality control ............................................................ 63 
11.3 Site monitoring  ...................................................................................................... 64 
12 Data analysis and statistical methods  ................................................................................ 65 
12.1 Analysis sets .......................................................................................................... 65 
12.2 Participant demographics and other baseline characteristics  ................................. 65 
12.3 Treatments  ............................................................................................................. 65 
12.4 Analysis of the primary endpoint(s)/estimand(s) .................................................. 66 
12.4.1 Definition of primary endpoint and estimand ....................................... 66 
12.4.2 Statistical model, hypothesis, and method of analysis .......................... 66 
12.4.3 Handling of remaining intercurrent events of primary estimand  .......... 66 
12.4.4 Handling of missing values not related to intercurrent event  ............... 67 
12.4.5 Sensitivity analyses for primary endpoint/estimand  ............................. 67 
12.4.6 Supplementary analysis ......................................................................... 67 
12.4.7 Supportive analyses  ............................................................................... 67 
12.5 Analysis of secondary endpoints/estimands  .......................................................... 67 
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s) .................................... 67 
12.5.2 Safety endpoints .................................................................................... 68 
12.5.3 Biomarkers  ............................................................................................ 69 
  70 
  70 

Novartis  Confidential  Page 5 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
  70 
12.7 Interim analyses  ..................................................................................................... 70 
12.8 Sample size calculation .......................................................................................... 71 
12.8.1 Primary endpoint(s)  ............................................................................... 71 
13 Ethical considerations and administrative procedures  ...................................................... 71 
13.1 Regulatory and ethical compliance ........................................................................ 71 
13.2 Responsibilities of the investigator and IRB/IEC  .................................................. 71 
13.3 Publication of study protocol and results............................................................... 72 
13.4 Quality Control and Quality Assurance  ................................................................. 72 
14 Protocol adherence  ............................................................................................................ 72 
14.1 Protocol amendments ............................................................................................. 73 
15 References  ......................................................................................................................... 74 
16 Appendices ........................................................................................................................ 77 
16.1 Appendix 1: Diagnostic criteria for FH in adolescents / children ......................... 77 
16.2 Appendix 2: Clinically notable laboratory values and vital signs ......................... 78 
16.3 Appendix 3: Liver event and laboratory trigger definitions & follow-up 
requirements .......................................................................................................... 79 
16.4 Appendix 4: Specific Renal Alert Criteria and Actions and Event Follow-up ...... 82 
16.5 Appendix 5: Recommended Neurological Examination ....................................... 84 
16.6 Appendix 6: Sampson Criteria for Diagnosing Anaphylaxis ................................ 88 
16.7 Appendix 7: Reference table blood volume by weight ......................................... 89 
List of tables  
Table 2 -1 Objectives and related endpoints .......................................................... 20 
Table 6 -1 Investigational and control drug ............................................................ 31 
Table 6 -2 Prohibited medication  ........................................................................... 33 
Table 6 -3 Guidance on specific clinical and diagnostic assessments which 
can be performed to rule out possible alternative causes of 
observed LFT abnormalities ................................................................. 37 
Table 8 -1 Assessment Schedule  ............................................................................ 43 
Table 8 -2 Assessments &  Specifications ............................................................... 49 
Table 8 -3 Laboratory Assessments  ........................................................................ 50 
Table 10-1 Guidance for capturing the study treatment errors including misuse/abuse ......................................................................................... 61
 
  71 
Table 16-1 Criteria for clinically notable vital signs  ............................................... 78 
Table 16-2 Clinically notable laboratory abnormalities for selected tests  .............. 78 
Table 16-3 Liver event and laboratory trigger definitions  ...................................... 79 

Novartis  Confidential  Page 6 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Table 16-4 Follow up requirements for liver laboratory triggers with liver 
symptoms .............................................................................................. 80 
Table 16-5 Follow up requirements for liver laboratory triggers  ............................ 81 
Table 16-6 Specific renal alert criteria and actions ................................................. 82 
Table 16-7 Renal event follow -up ........................................................................... 82 
Table 16-8 Grade Strength  ...................................................................................... 84 
Table 16-9 Reflex responses  .................................................................................... 86 
Table 16-10 Reference table – blood collection volumes by body weight ............... 89 
List of figures  
Figure 3-1 Study Design ......................................................................................... 24 
 
Novartis  Confidential  Page 7 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
List of abbreviations  
ADA Anti-drug antibodies  
ADR  Adverse Drug Reaction  
AE(s)  Adverse event(s)  
ALP Alkaline phosphatase  
ALT Alanine aminotransferase  
Apo A1  Apolipoprotein A1  
Apo B  Apolipoprotein B  
ASCVD  Atherosclerotic cardiovascular disease  
AST Aspartate aminotransferase  
ATC Anatomical Therapeutic Chemical   
BfArM  Federal Institute for Drugs and Medical Devices  
BMI Body Mass Index  
BUN  Blood urea nitrogen  
C(P)K  Creatine (phospho)kinase  
CFR Code of Federal Regulation  
CHD  Coronary heart disease  
CMO&PS  Chief Medical Office and Patient Safety  
CRF Case Report/Record Form (paper or electronic)  
CRO  Contract Research Organization  
CTFG  Clinical Trials Facilitation and Coordination Group  
CTT Clinical trial team  
CV Cardiovascular  
CVD  Cardiovascular disease  
DBP Diastolic Blood Pressure  
DILI Drug induced liver injury  
DIN Drug -induced nephrotoxicity  
DMC  Data Monitoring Committee  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
eGFR  Estimated glomerular filtration rate  
EOS  End of study  
ERCP  Endoscopic retrograde cholangiopancreatography  
EudraCT  European Union Drug Regulating Authorities Clinical Trials  
FAS Full Analysis Set  
FH Familial Hypercholesterolemia  
FPG Fasting plasma glucose  
GalNAc  N-Acteylgalactosamine  
GCP  Good Clinical Practice  
GGT  Gamma -glutamyl transferase  
GLDH  Glutamate dehydrogenase  
HbA1c  Hemoglobin A1c  
HDL-C High density lipoprotein cholesterol  

Novartis  Confidential  Page 8 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
HeFH  Heterozygous Familial Hypercholesterolemia   
HoFH  Homozygous Familial Hypercholesterolemia  
  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonisation (of Technical Requirements for Pharmaceuticals for 
Human Use)  
IEC Independent Ethics Committee  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
ISR(s)  Injection site reaction(s)  
IUD Intrauterine device  
IUS Intrauterine system  
kg Kilogram (s) 
LDL Low density lipoprotein  
LDL-C Low density lipoprotein cholesterol  
LDLR  Low density lipoprotein receptor  
  
LFT(s)  Liver function test(s)  
LLOQ  Lower limit of quantification  
Lp(a)  Lipoprotein (a)  
MCV  Mean corpuscular volume  
mg milligram(s)  
MI Myocardial infarction  
mL milliliter(s)  
MMRM  Mixed -effect model for repeated measures  
MRI Magnetic resonance imaging  
mRNA(s)  Messenger ribonucleic acid(s)  
PCR  Protein -creatinine ratio  
PCSK9  Proprotein convertase subtilisin/kexin type 9  
PD Pharmacodynamic(s)  
PEF Peak expiratory flow  
  
PT/INR  Prothrombin Time / International Normalized Ratio  
RBC  Red blood cell(s)  
RISC(s)  Ribonucleic acid (RNA) -induced silencing complex(es)  
RNA  Ribonucleic acid  
s.c. Subcutaneous  
SAE Serious adverse event  
SAP Statistical Analysis Plan  
SBP Systolic Blood Pressure  
SC Steering Committee  
sCr Serum creatinine  
SD Standard deviation  
siRNA(s)  Small interfering ribonucleic acid(s)  

Novartis  Confidential  Page 9 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
SoC Standard of Care  
SOP(s)  Standard Operating Procedure(s)  
SUSAR(s)  Suspected Unexpected Serious Adverse Reaction(s)  
TBV Total blood volume  
TEAE  Treatment emergent adverse event  
TSH Thyroid stimulating hormone  
ULN Upper limit of normal  
VLDL -C Very low density lipoprotein cholesterol  
WBC  White blood cell(s)  
Novartis  Confidential  Page 10 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Glossary of terms  
Additional 
treatment  Medicinal products that may be used during the clinical trial as described in the protocol, 
but not as an investigational medicinal product (e.g. any background therapy)  
Assessment  A procedure used to generate data required by the study  
Biologic Samples  A biological specimen including, for example, blood (plasma, serum), saliva, tissue, urine, 
stool, etc. taken from a study participant  
Cohort  A specific group of participants fulfilling certain criteria  
Control drug  Any study drug (an active drug or an inactive drug, such as a placebo) which is used as a 
comparator to reduce assessment bias, preserve blinding of investigational drug, assess 
internal validity, and/or evaluate comparative effects of the investigational drug 
Dosage  Dose of the study treatment given to the participant in a time unit (e.g. 100 mg once a 
day, 75 mg twice a day)  
Electronic Data 
Capture (EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical study data using 
data collection systems, such as Web-based applications, interactive voice response systems and clinical laboratory interfaces. EDC includes the use of Electronic Case 
Report Forms (eCRFs) which are used to capture data transcribed from paper source 
forms used at the point of care  
End of the clinical 
trial The end of the clinical trial is defined as the last visit of the last participant or at a later 
point in time as defined by the protocol   
Enrollment  Point/time of participant entry into the study; the point at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol).  
Estimand  A precise description of the treatment effect reflecting the clinical question posed by the 
trial objective. It summarizes at a population-level what the outcomes would be in the 
same patients under different treatment conditions being compared. Attributes of an 
estimand include the population, variable (or endpoint) and treatment of interest, as well 
as the specification of how the remaining intercurrent events are addressed and a 
population -level summary for the variable.  
Intercurrent events  Events occurring after treatment initiation that affect either the interpretation or the 
existence  of the measurements associated with the clinical question of interest.  
Investigational 
drug/ treatment  The drug whose properties are being tested in the study.  
Medication 
number  A unique identifier on the label of each study drug package in studies that dispense study 
drug using an IRT system.  
Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for randomization and who 
did not take study treatment, but have been inadvertently randomized into the study  
Other treatment  Treatment that may be needed/allowed during the conduct of the study (i.e. concomitant 
or rescue therapy)  
Part  A sub -division of a study used to evaluate specific objectives or contain different 
populations. For example, one study could contain a single dose part and a multiple dose part, or a part in participants with established disease and in those with newly -diagnosed 
disease  
Participant  A trial participant (can be a healthy volunteer or a patient)  
Participant number  A unique number assigned to each participant upon signing the informed consent. This number is the definitive, unique identifier for the participant and should be used to identify 
the participant throughout the study for all data collected, sample labels, etc.  
Period A minor subdivision of the study timeline; divides phases into smaller functional segments 
such as screening, baseline, titration, washout, etc.  
Personal data  Participant information collected by the Investigator that is coded and transferred to Novartis for the purpose of the clinical trial. This data includes participant identifier 
information, study information and biological samples.  
Premature participant 
withdrawal  Point/time when the participant exits from the study prior to the planned completion of all study drug administration and/or assessments; at this time all study drug administration is 
discontinued and no further assessments are planned  
Novartis  Confidential  Page 11 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Randomization 
number  A unique identifier assigned to each randomized participant  
Screen Failure  A participant who did not meet one or more criteria that were required for participation in 
the study  
Source 
Data/Document  Source data refers to the initial record, document, or primary location from where data 
comes. The data source can be a database, a dataset, a spreadsheet or even hard-
coded data, such as paper or eSource  
Start of the clinical 
trial The start of the clinical trial is defined as the signature of the informed consent by the first 
participant  
Study treatment  Any drug administered to the study participants as part of the required study procedures; 
includes investigational drug(s), control(s) or background therapy  
Study treatment 
discontinuation  When the participant permanently stops taking any of the study drug(s) prior to the 
defined study treatment completion date (if any) for any reason; may or may not also be 
the point/time of study discontinuation   
Treatment 
arm/group  A treatment arm/group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts.  
Treatment of 
interest  The treatment of interest and, as appropriate, the alternative treatment to which 
comparison will be made. These might be individual interventions, combinations of 
interventions administered concurrently, e.g. as add-on to standard of care, or might 
consis t of an overall regimen involving a complex sequence of interventions. This is the 
treatment of interest used in describing the related clinical question of interest, which 
might or might not be the same as the study treatment.  
Variable (or 
endpoint)  The variable (or endpoint) to be obtained for each participant that is required to address 
the clinical question.  The specification of the variable might include whether the 
participant experiences an intercurrent event.  
Withdrawal of 
study consent  Withdrawal of consent from the study occurs only when a participant does not want to 
participate in the study any longer and does not allow any further collection of personal 
data  
Novartis  Confidential  Page 12 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Amendment 2 ( 17-Feb-2023)  
Amendment rationale  
 
 
 
  
  
 
 
 
 
        
 
 
 
 
Changes to the protocol  
The revisions made to the protocol are listed in the Table below.  
Section  Description of change  
List of abbreviations  An abbreviation associated with the current amendment is added.  
 
  
  
  
Changes to specific sections of the protocol are shown in the track changes version of the protocol using strike through red font for deletions and red underlined for insertions.  
Institutional Review Boards ( IRBs ) / Independent Ethics Committees ( IECs ) 
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  

Novartis  Confidential  Page 13 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
The changes described in this amended protocol require IRB/IEC and Health Authority 
approval according to local regulations prior to implementation.  
The changes herein do not affect the Informed Consent.  
Summary of previous amendments 
Amendment 1  (28-Oct-2022)  
Amendment rationale  
 
  
 
 
 
 
  
    
  
                
 
   

Novartis  Confidential  Page 14 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
In addition , several small clarifications/corrections/additions are 
included in this protocol amendment:  
  
 
 
       
   
  
  
   
  
   
  
    
• A minor spelling error is corrected.  
This amendment is issued after the release of the original protocol version 00 . The first 
participant for this trial was screened on 27 -Jan-2021.  
Changes to the protocol  
The revisions made to the protocol are listed in the Table below.  
Section  Description of change  
Changes related to the sample size reduction  
List of abbreviations  Abbreviations associated with the current amendment are added.  
   
 
  
 
 
  
 
 
  
 

Novartis  Confidential  Page 15 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Section  Description of change  
 
  
 
Other small clarifications/corrections/additions   
   
  
 
 
  
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
  
 
 
  
  
 
 
  
 
Section 15  References  New references associated with the current amendment are added.  

Novartis  Confidential  Page 16 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Protocol summary  
Protocol 
number  CKJX839C12301  
Full Title  Two part (double -blind inclisiran versus placebo [Year 1] followed by open -label inclisiran 
[Year 2]) randomized multicenter study to evaluate safety, tolerability, and efficacy of 
inclisiran in adolescents (12 to less than 18 years) with heterozygous familial 
hypercholesterolem ia and elevated LDL -cholesterol (ORION -16) 
Brief title  A multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in adolescents 
(12 to less than  18 years) with heterozygous familial hypercholesterolemia   
Sponsor and 
Clinical Phase  Novartis / Phase III  
Investigation 
type Drug  
Study type  Interventional  
Purpose and 
rationale This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of 
inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and 
elevated low density lipoprotein cholesterol (LDL-C). The use of inclisiran for the treatment 
of HeFH in adolescent patients who require additional lipid lowering will be investigated in 
order to obtain needed pediatric info rmation on inclisiran.  
Primary 
Objective(s)  The primary objective of the study is to demonstrate superiority of inclisiran compared to 
placebo in reducing LDL- C [percent change] at Day 330 (Year 1) in adolescents (aged 12 
to <18 years) with HeFH and elevated LDL -C. 
Secondary 
Objectives Demonstrate superiority of inclisiran compared to placebo in reducing LDL -C [time -adjusted 
percent change] over Year 1  
Demonstrate superiority of inclisiran compared to placebo in reducing LDL- C [absolute 
change] at Day 330 (Year 1)  
Demonstrate superiority of inclisiran compared to placebo in reducing apolipoprotein B (Apo B), lipoprotein (a) [Lp(a)], non-high density lipoprotein cholesterol (non-HDL -C), and 
total cholesterol [percent change] at Day 330 (Year 1)  
Evaluate the effect of inclisiran, compared to placebo (for Year 1) and long -term (up to Day 
720), on lowering LDL-C, other lipoprotein and lipid parameters, and proprotein convertase 
subtilisin/kexin type 9 (PCSK9) over time  
Evaluate the safety and tolerability profile of inclisiran, compared to placebo (for Year 1) 
and long -term (up to Day 720), in adolescents (aged 12 to <18 years) with HeFH  
Study design  Two part (double -blind inclisiran versus placebo [Year 1] followed by open -label inclisiran 
[Year 2]) randomized multicenter study   
Study 
population  Adolescents (age 12 to <18 years) with HeFH; a minimum of 102 participants  (actual 
expected number of participants:  approximately 130); males and females  
Key Inclusion 
criteria  • HeFH diagnosed either by genetic testing or on phenotypic criteria  
• Fasting LDL-C >130 mg/dL (3.4 mmol/L) at screening  
• Fasting triglycerides <400 mg/dL (4.5 mmol/L) at screening  
• On maximally tolerated dose of statin (investigator’s discretion) with or without other 
lipid-lowering therapy (e.g. ezetimibe). Maximum tolerated dose of statin is defined as 
the maximum dose of statin that, at the investigator’s discretion, can be taken on a 
regular basis without adverse events that would lead to a reduction in statin dose  
• Participants on lipid- lowering therapies (such as statin and/or e.g. ezetimibe) should be 
on a stable dose for ≥ 30 days before screening with no planned medication or dose 
changes during study participation  
• Participants on a documented regimen of LDL-apheresis will be allowed to continue the 
apheresis during the study, if needed. The apheresis schedule is not allowed to change 
during the double- blind period of the trial and must permit that an apheresis coinc ides 
with each study visit  
• Estimated glomerular filtration rate  (eGFR) >30 mL/min/1.73 m2 at screening  
Key Exclusion 
criteria  • Previous treatment (within 90 days of screening) with monoclonal antibodies directed 
towards PCSK9  
Novartis  Confidential  Page 17 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
• Active liver disease or unexplained, confirmed alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) elevation >3x ULN, or total bilirubin elevation >2x 
ULN (except patients with Gilbert’s syndrome)  
• Pregnant or nursing females  
• Homozygous familial hypercholesterolemia (HoFH)  
• Recent and/or planned use of other investigational medicinal products or devices  
• Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome  
• Major adverse cardiovascular events within 3 months prior to randomization  
Study 
treatment  Part 1 (Year 1):  
• Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran*) in 1.5 mL solution  
• Placebo  
Part 2 (Year 2):  
• Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran*) in 1.5 mL solution  
• * Inclisiran is also referred to as KJX839.  
Treatment of 
interest  The randomized treatment (the investigational treatment inclisiran or the control treatment 
placebo) as add-on to optimal standard of care lipid-lowering therapy for HeFH. The type and dose of the concomitant lipid- lowering therapy for HeFH must remain stable during 
Part 1 (Year 1) of the study.  
Efficacy 
assessments  The primary efficacy assessment will be LDL -C 
Other efficacy assessments will include:  
• Apo B, Lp(a), non-HDL -C, total cholesterol, triglycerides, high density lipoprotein 
cholesterol (HDL-C), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein 
A1 (Apo A1), PCSK9  
Key safety 
assessments  Adverse event (AE) monitoring, vital signs, laboratory parameters (blood and urine), anti -
drug antibodies (ADA) measurement, growth, pubertal development  
 
   
 
Data analysis  The analysis for the primary objective will test the null hypothesis of no difference between 
participants treated with inclisiran and placebo in the least squares mean percentage change from baseline to the Day 330 visit in LDL-C against an alternative hypothesis of 
superiority of inclisiran treatment. A one-sided significance level of 0.025 will be used in this 
test. The primary analysis will use an analysis of covariance (ANCOVA) model. The model 
will include the fixed effects of treatment group and baseline age group with baseline LDL-
C as a covariate. Multiple imputation will be used to impute missing data using a washout 
model. The difference in least squares means between treatment groups and 
corresponding 2-sided 95% confidence intervals will be calc ulated.  
A hierarchical testing strategy will be applied to control the family -wise type I error rate at 
the one-sided significance level of alpha=0.025 to assess superiority of inclisiran over 
placebo for key secondary endpoints: time-adjusted percent change in LDL-C from 
baseline after Day 90 and up to Day 330, absolute change in LDL- C from baseline to Day 
330, percent change in Apo B from baseline to Day 330, percent change in Lp(a) from baseline to Day 330, percent change in non- HDL-C from baseline to Day 330, and percent 
change in total cholesterol from baseline to Day 330.  The analysis of key secondary 
endpoints will use ANCOVA with missing data imputed using the washout model.  
Safety analyses will include summaries of the incidence of AEs, laboratory parameters, 
ADA measurements, vital signs, and maturation.  
The sample size provides more than 90% power to detect a 30% reduction in the inclisiran 
group compared to the placebo group in percent change of LDL -C from baseline.  
Key words  Heterozygous familial hypercholesterolemia (HeFH), LDL -cholesterol (LDL -C), adolescents, 
pediatric, small interfering ribonucleic acid (siRNA)  

Novartis  Confidential  Page 18 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
1 Introduction  
1.1 Background 
Despite advances in treatment, cardiovascular disease (CVD) is the leading cause of death 
worldwide, resulting in over 17 million deaths annually ( WHO  2017). Eighty percent of all 
CVD deaths are due to coronary heart disease (CHD) or strokes. Elevated low density lipoprotein cholesterol (LDL -C) is a major risk factor for the development of CVD 
(Grundy et  al 2004, Go et al 2014 ). Lowering LDL -C has been shown to reduce the risk of 
death or heart attack and within the range of effects achieved so far, the clinical risk reduction is linearly proportional to the absolute LDL -C reduction ( Baigent et al 2005, 
Giugliano et  al 2017).  
Millions of people worldwide are treated with lipid -lowering therapies, predominantly statins, 
to reduce LDL -C and the associated risk of death, nonfatal myocardial infarction (MI) and 
nonfatal stroke or associated events ( Casula et  al 2012). Despite the availability of statins alone 
or in combination with other lipid -lowering medications, with current therapies for the 
management of elevated LDL -C, many at -risk patients do not reach LDL -C goals 
(Jones et  al 2012, Jameson  et al 2014, Barkas  et al 2015, Fitzgerald  et al 2017 ). This is 
particularly true in patients with pre -existing CHD and/or diabetes or a history of familial 
hypercholesterolemia (FH), who are at the highest risk and require the most intensive management ( Davidson et  al 2005 ). 
FH is a genetic disorder that causes high levels of LDL -C in the blood and is characterized by 
premature cardiovascular (CV) disease. It is caused by mutations in genes encoding proteins which regulate low density lipoprotein receptor (LDLR) -mediated clear ance of LDL -C, 
including (in decreasing order of prevalence) LDLR, apolipoprotein B (Apo B), and proprotein convertase subtilisin/kexin type 9 (PCSK9) ( Santos et  al 2016). There are two clinical 
manifestations depending on the presence of one or two affected alleles in these genes. The milder heterozygous form (heterozygous familial hypercholesterolemia [HeFH]) results from a single affected allele.  The more severe homozy gous form (homozygous familial 
hypercholesterolemia [HoFH]) results from biallelic pathogenic variants in one of these genes, or one pathogenic variant in each of two different genes ( Santos et  al 2016 ). 
Recent studies suggest that FH is more common than previously projected, with 1/160,000 to 1 in 300,000 estimated to have HoFH and 1/200 to 1 in 250 people (instead of the historical 1/500) to have HeFH ( Najam  and Ray 2015, Wiegman  et al 2015 ). There are an estimated 34 million 
people with FH worldwide, but the majority remain undiagnosed (~90%) and current treatment is often suboptimal ( Wilemon  et al 2020).  
Children with HeFH are usually asymptomatic in childhood and adolescence and are typically diagnosed by the established FH screening methods ( Varghese 2014). The total cholesterol and 
LDL -C levels of these children are often over the 95th percentile of the recommended levels, 
and a positive family history corroborates the diagnosis. Some children with HeFH may present with tendon xanthoma or arcus lipoides ( Varghese 2014). In FH, elevations in LDL -C occur 
from birth ( Santos et  al 2016). Although atherosclerosis resulting from FH manifests primarily 
in adulthood, growing evidence suggests that it may begin in childhood (as early as the first decade of life) and is directly associated with the same CVD risk factors that are well established in adults ( Daniels et  al 2011).  
Novartis  Confidential  Page 19 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
As the degree and duration of exposure to elevated LDL -C levels increases the atherosclerotic 
burden, early treatment of FH to lower LDL -C levels is vital (Varghese 2014). In accordance 
with recommendations from the Expert Panel on Integrated Guidelines for Cardiovascular 
Health and Risk Reduction in Children and Adolescents, a LDL -C target of ≤130 mg/dL is 
recommended in children/adolescents ( Expert Panel  2011). Expert consensus recommends that 
lipid-lowering treatment consisting of lifestyle recommendations and pharmacological therapy 
should be started from 8 to 10 years of age in patients with FH and should be maintained for life (Wiegman  et al 2015). Guidelines further recommend statins as first line drug therapy for 
lipid lowering in children ( Daniels et al 2011, Expert Panel  2011, Gidding et  al 2015, 
Newman  et al 2019), however, multiple drug therapy is often needed ( Youngblom et  al 2016).  
Current treatment options are still limited for children with FH, and the known limitations of contemporary therapies are particularly relevant among children with FH who are at the highest risk of future CV events, and thus require the most intensive and aggressive management of hypercholesterolemia ( Stone et  al 2014). Thus, there remains a clear unmet medical need for 
treatments that will lower LDL -C, especially in pediatric populations.  
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the serine protease family, plays a key role in controlling the levels of LDLRs on the surface of hepatocytes (Khvorova 2017). PCSK9 is expressed and secreted into the bloodstream predominantly by the 
liver, binds LDLR both intracellularly and extracellularly and promotes the lysosomal degradation of these receptors in hepatocytes, ( Lakoski et  al 2009, Mousavi et  al 2009 ) thereby 
increasing the circulating LDL -C levels.  
Recently developed and approved PCSK9-blocking monoclonal antibodies reduce PCSK9 and lower LDL -C levels, and were also shown to significantly reduce the risk of CV events 
(Sabatine et  al 2017, Schwartz et  al 2018).  
Small interfering ribonucleic acids (siRNAs) selectively and catalytically silence the translation of their complimentary target messenger ribonucleic acids (mRNAs) in a sequence specific manner through the formation of effector ribonucleic acid (RNA)-induced silencing complexes (RISCs), utilizing a highly specific endogenous mechanism for regulating gene expression (Ray et al 2019). Inclisiran is a chemically modified double -stranded small interfering RNA, 
conjugated on the sense strand with triantennary N -Acetylgalactosamine (GalNAc) to facilitate 
uptake by hepatocytes. In hepatocytes, the antisense strand is incorporated in the R ISC and 
directs catalytic breakdown of mRNA for PCSK9. This inhibits translation of PCSK9 protein. Reduced intrahepatic PCSK9 increases LDLR recycling and expression on the hepatocyte cell surface, thereby increasing LDL -C uptake and lowering LDL -C levels in the circulation 
(Fitzgerald  et al 2017 ). 
In the ORION clinical development program, 3660 participants with atherosclerotic CV disease (ASCVD), ASCVD risk equivalent, and/or HeFH were studied in three confirmatory 18 -months 
phase III studies comparing inclisiran versus placebo adjunctive to maximally tolerated statin therapy, and an additional 681 participants were treated in phase I and phase II studies. In the phase III studies, treatment with inclisiran sodium 300 mg given by subcutaneous (s.c.) injection on Day 1, Day 90, and every 6 months thereafter, resulted in placebo -adjusted 
percentage reductions in LDL -C from baseline at Day 510 of 48% to 52%, with time -adjusted 
average reductions of 44% to 54% sustained over 18 months ( Raal et al 2020, Ray et al 2020). 
Novartis  Confidential  Page 20 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
The efficacy of inclisiran was consistent across phase I, phase II and phase III studies, with no 
differences across a broad range of subpopulations. 
There were no clinically relevant differences in the safety profile of inclisiran compared with 
placebo, except for a higher incidence of treatment -emergent adverse events (TEAEs) at the 
injection site with inclisiran. However, all TEAEs at the injection s ite were localized, 
predominantly mild, transient, and resolved without sequelae. Inclisiran is not associated with an increased risk for hepatic or renal dysfunction, hypersensitivity, neurologic events and neurocognitive disorders, or ophthalmological events and there was no difference from placebo in new onset or worsening of diabetes. The potential for immunogenicity of inclisiran is low. Additional details on the efficacy and safety of inclisiran are available in the Investigator's Brochure (IB). 
Based on the established benefit -risk profile in adults, inclisiran may improve the treatment of 
children/adolescents with HeFH, with a low injection burden given the only twice yearly 
dosing. 
Study CKJX839C12301 (ORION -16) is planned to investigate inclisiran in adolescents aged 
12 to <18 years of age with HeFH. 
1.2 Purpose 
Study CKJX839C12301 (ORION -16) is a pivotal phase III study designed to evaluate safety, 
tolerability, and efficacy of inclisiran in adolescents (aged 12 to <18 years) with HeFH and 
LDL -C >130 mg/dL (3.4 mmol/L). The use of inclisiran (as an adjunct to sta ble, optimal 
background lipid- lowering therapy) for the treatment of HeFH in adolescent patients who 
require additional lipid -lowering will be investigated in order to obtain needed pediatric 
information on inclisiran. The follow -up period (Part 2/Year 2) serves to collect longer -term 
data on inclisiran and also allows access of study participants to a potentially effective treatment.  
2 Objectives and endpoints  
Table 2-1 Objectives and related endpoints 
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
• The primary objective is to demonstrate 
superiority of inclisiran compared to placebo in reducing LDL-C [percent change] at Day 
330 (Year 1) in adolescents (aged 12 to <18 
years) with HeFH and elevated LDL -C  • Percentage change in LDL-C from baseline to Day 330 (Year 1)  
See Section 2.1 for primary estimand  
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
• Demonstrate superiority of inclisiran 
compared to placebo in reducing LDL-C 
[time -adjusted percent change] over Year 1  • Time -adjusted percent change in LDL-C from baseline 
after Day 90 and up to Day 330 (Year 1)  
• Demonstrate superiority of inclisiran compared to placebo in reducing LDL-C 
[absolute change] at Day 330 (Year 1)  • Absolute change in LDL-C from baseline to Day 330 
(Year 1)  
Novartis  Confidential  Page 21 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Objective(s)  Endpoint(s)  
• Demonstrate superiority of inclisiran 
compared to placebo in reducing Apo B, 
lipoprotein (a) [Lp(a)], non- high density 
lipoprotein cholesterol (non-HDL -C), and 
total cholesterol [percent change] at Day 
330 (Year 1)  • Percent change in Apo B, Lp(a), non-HDL -C, and total 
cholesterol from baseline to Day 330 (Year 1)  
• Evaluate the effect of inclisiran, compared 
to placebo (for Year 1) and long-term (up to 
Day 720), on lowering LDL-C, other 
lipoprotein and lipid parameters, and 
PCSK9 over time  • Percent change and absolute change in LDL -C, Apo B, 
Lp(a), non-HDL -C, total cholesterol, triglycerides, high 
density lipoprotein cholesterol (HDL-C), very low density 
lipoprotein cholesterol (VLDL- C), apolipoprotein A1 (Apo 
A1) and PCSK9 from baseline to each assessment time 
up to Day 720 (Year 2)  
• Evaluate the safety and tolerability profile of inclisiran, compared to placebo (for Year 1) and long-term (up to Day 720), in 
adolescents (aged 12 to <18 years) with HeFH  • Incidence, severity and relationship to study drug of 
treatment -emergent adverse events (AEs) and serious 
adverse events (SAEs); vital signs; laboratory 
parameters; anti -drug antibodies (ADA) measurement; 
growth (height, weight, body mass index (BMI)); pubertal 
development (steroid hormones and Tanner staging)  
2.1 Primary estimands  
The primary clinical question of interest is: What is the effect of the test treatment versus 
placebo on change in LDL -C after 330 days of treatment in adolescents with HeFH who are 
on stable, optimal standard of care (SoC) lipid -lowering therapy, regardle ss of treatment 
discontinuation for any reason and regardless of unforeseen change in the concomitant lipid -
lowering therapy.  
The justification for the primary estimand is that it will capture both the effect of the study drug and the effect of changes in additional medication(s) used for HeFH, if they occur, as would be the case in clinical practice.  
The primary estimand is described by the following attributes:  

Novartis  Confidential  Page 22 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
1. Population: Adolescents with the HeFH condition of interest and elevated LDL -C on stable 
optimal SoC lipid -lowering therapy. Further details about the population are provided 
in Section  5. 
2. Endpoint: Percentage change in LDL- C from baseline to Day 330 (Year 1).  
3. Treatment of interest: The randomized treatment (the investigational treatment inclisiran or 
the control treatment placebo) as add -on to optimal SoC lipid -lowering therapy for HeFH. 
The type and dose of the  concomitant lipid -lowering therapy for HeFH must remain stable 
during Part 1 (Year 1) of the study. Further details about the investigational treatment and 
control treatment are provided in  Section  6. 
The summary measure: difference between treatments in  least squares mean percentage change 
at Day 330. 
2.2 Secondary estimands  
Secondary estimands corresponding to key secondary efficacy endpoints are defined similarly to the primary estimand. These endpoints, and the corresponding summary measures, are listed 
below. Population, treatment of interest, endpoints, and intercurrent events are defined similarly 
as for the primary estimand.  
• Endpoint: time -adjusted percent change in LDL -C from baseline after Day 90 and up to Day 
330 (Year 1). Summary measure: difference between treatment groups in least squares mean time-adjusted percent change in LDL -C from baseline after Day 90 and up to Day  330 (Year 
1). 
• Endpoint: absolute change in LDL -C from baseline to Day 330 (Year 1). Summary 
measure:  difference between treatment groups in  least squares mean  absolute change in 
LDL -C from baseline to Day 330 (Year 1). 
• Endpoint: percent change in Apo B from baseline to Day 330 (Year 1). Summary measure:  difference between treatment groups in least squares mean  percent  change in Apo 
B from baseline to Day 330 (Year 1). 
• Endpoint: percent  change in Lp(a) from baseline to Day 330 (Year 1). Summary 
measure:  difference between treatment groups in  least squares mean  percent  change in 
Lp(a) from baseline to Day 330 (Year 1). 
• Endpoint: percent  change in non- HDL -C from baseline to Day 330 (Year 1). Summary 
measure:  difference between treatment groups in  least squares mean  percent  change in non-
HDL -C from baseline to Day 330 (Year 1). 
• Endpoint: percent  change in total cholesterol from baseline to Day 330 (Year 1). Summary 
measure:  difference between treatment groups in  least squares mean  percent  change in total 
cholesterol from baseline to Day 330 (Year 1).  
3 Study design  
This study is a two -part (double -blind, placebo- controlled / open -label) multicenter study in 
adolescents (aged 12 to <18 years) with HeFH and elevated LDL -C (>130 mg/dL / 3.4 mmol/L) 
on stable, individualized, optimal SoC background lipid- lowering therapy  (including 
maximally tolerated statin treatment).  
Novartis  Confidential  Page 23 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
The overall study duration is 748 days (excluding a safety follow -up call 30 days after the end 
of study (EOS) visit).  
Following an approximately 4 weeks screening/run- in period, the study has two sequential parts 
(Figure 3-1).  
• Part 1 (Year 1): 12 months double -blind, parallel group period in which participants will 
be randomized to receive either inclisiran sodium 300 mg (equivalent to 284 mg inclisiran*) 
s.c. or placebo (given at Days 1, 90 and 270). 
• Part 2 (Year 2): 12 months single arm, open- label follow -up period with all participants 
receiving inclisiran sodium 300 mg (equivalent to 284 mg inclisiran*) s.c. Participants 
randomized to placebo in Part 1 will receive inclisiran starting on Day 360 (“Switch” Day 
360). Participants randomized to inclisiran in Part 1 will receive placebo on Day 360. This dose of inclisiran/placebo on Day 360 will remain blinded in order to maintain the blind for Part 1 of the study. All participants will receive subsequen t doses of open- label inclisiran 
on Days 450 and 630. 
* Inclisiran is also referred to as KJX839.  
Informed consent will be obtained before initiation of any study- specific procedures (see 
Section  5.1 and Section  7 for details). Participants who meet the inclusion/exclusion criteria 
will be required to maintain their current lipid -lowering treatment unchanged for Part 1 (Year 
1) of the study (including the screening/run -in period). Investigators must ensure that each 
participant receives individualized, optimal SoC lipid -modifying treatment [including 
maximally tolerated statin treatment (investigator’s discretion) with or without other lipid -
lowering therapy (e.g. ezetimibe)], and that this treatment was stable for ≥ 30 days before screening. Maximum tolerated dose of statin is defined as the maximum dose of statin that, at the investigator’s discretion, can be taken on a regular basis without AEs that would lead to a reduction in statin dose. Intolerance to statin m ust be documented and enrollment of statin-
intolerant participants will be capped at approximately 15%.  
A minimum of 102 participants (actual expected number of participants: approximately 130) 
who meet the inclusion/exclusion criteria will be randomized in a 2:1 ratio to receive either inclisiran sodium 300 mg s.c. or placebo on Day 1 (baseline). Randomization will be stratified by age (≥12 to <15 years and ≥15 to <18 years to include a minimum of 40 participants in each 
of the two age strata). A second and third dose of inclisiran or placebo will be given on Day 90 and Day 270, respectively. The primary endpoint will be measured at Day 330. 
Participants initially randomized to placebo will transition to inclisiran starting on Day 360 and 
the study will then change to an open- label, single arm follow -up period of inclisiran sodium 
300 mg s.c. (Part 2). In order to maintain the blind for Part 1  of the study, on the “switch” day 
(Day 360), participants randomized to placebo in Part 1 will receive blinded inclisiran, while participants randomized to inclisiran in Part 1 will receive blinded placebo. All participants will receive subsequent doses of open-label inclisiran on Day 450 and Day 630. 
The EOS visit will be on Day 720. In addition, a safety follow -up call will be conducted 30 
days after the last study visit or 90 days after the last administration of study drug, whatever is 
longer. 
Novartis  Confidential  Page 24 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Figure 3-1 Study Design 
  
* Primary endpoint assessed at Day 330. # "Switch Day": Participants randomized to placebo in Part 1 
will start to receive inclisiran on Day 360. Participants randomized to inclisiran in Part 1 will receive 
placebo on Day 360 only to maintain the blind for Part 1.  
Inclisiran and placebo will be administered exclusively by a health care provider at the study site. Participants will be observed in the clinic for at least 4 hours post injection on Day 1 and Day 360 (i.e. first dosing of inclisiran) and for at least 30 minutes post injection for all other 
dosing visits before being discharged. 
Participants on a documented regimen of low density lipoprotein (LDL) -apheresis will be 
allowed to continue their same regimen during the study, if needed. The apheresis schedule is 
not allowed to change during Part 1 (Year 1) of the study (including the s creening/run -in 
period). The apheresis schedule must also allow that an apheresis coincides with each study visit. Study drug is to be administered the same day, after completion of apheresis (the next scheduled apheresis should not occur within 72 hours after an administration of study drug). Blood samples for LDL -C (and other laboratory assessments of efficacy and safety) must be 
obtained immediately before the scheduled apheresis treatment at each applicable study visit (including screening and baseline (Day 1)). 
4 Rationale  
4.1 Rationale for study design  
Part 1 of the study (Year 1) has a randomized, parallel group, placebo- controlled design to 
provide evidence for the efficacy, safety, and tolerability of inclisiran in adolescents with HeFH. This study design is the most appropriate trial design to answer the clinical questions of interest  
on the use of inclisiran in this pediatric patient population.  

Novartis  Confidential  Page 25 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
The open- label single -arm design for Part 2 of the study (Year 2) is appropriate to obtain 
additional long- term data, with a maximum number of participants exposed to the 
investigational drug. 
A screening/run- in period of approximately 4 weeks is used to ensure the entry criteria are met 
(allowing test results to be received) and to ensure stabilization of individualized, optimal SoC 
background lipid -lowering therapy prior to randomization. 
An unequal 2:1 randomization was chosen in agreement with regulatory authorities. This unequal randomization allows to maximize exposure to the active investigational drug and to enhance collection of corresponding efficacy/safety information in the pediat ric study 
population. 
4.1.1 Rationale for choice of background therapy 
It is required that all participants receive individualized, optimal SoC lipid -lowering treatment 
for HeFH at study entry, which must remain unchanged for Part 1 (Year 1) of the study 
(including the screening/run- in period). Optimal SoC for adolescents wit h HeFH comprises 
maximally tolerated statin treatment with or without additional lipid -lowering treatment (e.g. 
ezetimibe), in accordance with international/local practice and treatment guidelines as well as regulatory authorities. No specific background medication is required during the conduct of the study; any statin and other lipid -lowering therapies approved for use in this population may be 
used (unless specifically prohibited per protocol; see Section  5.2 and Section  6.2.2 for details).  
4.2 Rationale for dose/regimen and duration of treatment  
The established dose regimen for inclisiran for adults is 300 mg s.c. on Day 1, Day 90 and every 6 months thereafter. Based on nonclinical and clinical data, including phase I, II and III clinical studies as well as pharmacodynamic (PD) modeling in adult participants, the same dose and dose regimen will also be used in the present study in adolescents. 
In adult participants, maximum reductions in LDL -C and PCSK9 levels with inclisiran were 
achieved with single s.c. doses of 300 mg inclisiran sodium, with no additional meaningful 
benefit observed at higher doses. Three large pivotal phase III studies in adult participants with ASCVD, ASCVD risk equivalents, and/or HeFH demonstrated that the dose regimen used in the present study (300 mg inclisiran sodium s.c. on Day 1, Day 90 and every 6 months thereafter) resulted in placebo -adjusted percentage reductions  in LDL -C from baseline at Day 
510 of 48% to 52%, with time -adjusted average reductions of 44% to 54% sustained over 18 
months. This dose and regimen also showed good tolerability of inclisiran, with a safety profile similar to placebo, except for a higher incidence of AEs at the injection site with inclisiran. No patient populations were identified that required an inclisiran dose adjustment. Doses up to 900 mg (3 -fold therapeutic dose) were studied which was safe and well tolerated in healthy adult 
subjec ts. 
Adult data has shown that the plasma PK of inclisiran does not predict PD effects. Inclisiran is rapidly cleared from plasma in 24 to 48 hours depending on the dose level, yet because of its site and mechanism of action, its LDL -C lowering effect is measur able for more than 6 months 
even after a single dose, the basis of the 6- monthly dosing interval. Inclisiran is delivered to 
hepatocytes due to its conjugated structure with GalNAc and stored intracellularly in RISC complexes, where target protein suppression occurs for months, resulting in the disconnect 
Novartis  Confidential  Page 26 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
between plasma PK and PD effects. In view of this time dissociation between PK and PD data, 
a plasma concentration vs. PD effect relationship cannot be established. From phase I study data, only a weak relationship was observed between inclisiran C
max and minimum LDL -C 
levels, due to the indirect processes involved between s.c. administration of inclisiran and reduction of LDL -C in the bloodstream. Additionally, after multiple administrations in the 
phase I study, inclisiran plasma exposure ratios were clos e to one, indicating no PK 
accumulation. A modelling and simulation analysis based on phase II study (ORION -1) data in 
adults suggest that the PD effect of inclisiran neither strengthens nor attenuates over time after repeated administrations up to 2 years  of treatment.  
In general, dosing and PK in adolescents are similar to those in adults ( Momper et  al 2013 ). 
Pharmacokinetics of inclisiran is expected to be similar in adolescents and adults as inclisiran is metabolized by exonuclease and endonuclease activity, with urinary excretion contributing to plasma elimination. Hence, the 300 mg dose, which has been shown to be efficacious, safe and well tolerated in adult phase III studies, as mentioned above, has been chosen as the dose for this study.  
 
 
The rationale for the approximately 1 year duration of the placebo- controlled Part 1 of the study 
is that it allows a reasonable number of 3 injections per participant (given the twice yearly dosing regimen) and is supported by the treatment effect observe d in the phase III clinical trials 
(up to 18 months). The duration is also suitable to assess the longer -term efficacy as well as 
safety and tolerability, including safety areas of special interest. The additional approximately 1-year duration of the uncontrolled Part 2 of the study is suitable to collect meaningful 
additional long- term data on inclisiran.  
4.3 Rationale for choice of control drugs (comparator/placebo)  
Part 1 of the study (which includes assessment of the primary (Efficacy) endpoint) is placebo -
controlled, which is a standard design in drug development to assess efficacy and safety and  
ensures that differences in outcome will be a reliable/realistic measure of the treatment effect of inclisiran. The use of placebo as a comparator is justified since all enrolled participants will be treated with individualized, optimal SoC (including maximum tolerated statin ± other lipid -
lowering treatment, e.g. ezetimibe ) prior to the addition of study treatment.  
Part 2 (1 year Safety follow -up) does not have a comparator arm; all patients will receive 
inclisiran, which represents a common and appropriate design to enable the collection of additional long- term safety data for the investigational drug for a maximum number of 
participants.  
4.4 Purpose and timing of interim analyses/design adaptations  
An independent Data Monitoring Committee (DMC) will review safety data regularly during the study. A recommendation may be taken to stop or amend the study at any of these reviews. Further details are provided in Section  10.2.4 and Section  12.7. 
 
 

Novartis  Confidential  Page 27 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
 
         
 
4.5 Risks and benefits  
It is widely recognized that LDL -C plays a major role in the initiation and progression of 
ASCVD, including in HeFH, and accumulated exposure of elevated LDL -C is causally related 
to the development of ASCVD. As the degree and duration of exposure to eleva ted LDL -C 
levels increases the atherosclerotic burden, early treatment of HeFH is vital. Published expert guidelines recommend a LDL -C target of ≤130 mg/dL in children/adolescents. Current 
treatment options to achieve these targets are still limited for children with FH and the well-known limitations of contemporary therapies are particularly relevant among pediatric patients with FH.  
In adult studies in participants with ASCVD, ASCVD risk equivalents, and/or HeFH, inclisiran given on Day 1, Day 90 and every 6 month thereafter lowered LDL -C by ~50% versus placebo 
in participants on maximally tolerated statin therapy ± other lipid -loweri ng therapies. The effect 
was persistent over time and reversible on stopping inclisiran.  
In non- clinical toxicity studies, inclisiran was not carcinogenic or genotoxic, there was no effect 
on paternal performance, spermatogenesis, estrous cycle, and uterine or ovarian parameters and inclisiran did not show evidence of embryolethality, fetotoxicity, or teratogenicity. In addition, there were no effects of inclisiran on the development of the F1 generation, including survival, growth, physical and reflexological development, behavior, and reproductive performance. The safety profile of inclisiran  in clinical studies was generally comparable to placebo. The only 
Adverse drug reaction (ADR) identified in clinical studies was a higher incidence of TEAEs at 
the injection site with inclisiran (preferred terms of injection site erythema, injection site 
hypersensitivity, injection site pruritus, injection site rash, and injection site reaction). However, all TEAEs at the injection site were localized, were predominantly mild or occasionally moderate, transient, and resolved without sequelae. The impact of  this side effect is further 
mitigated by the infrequent dosing regimen of inclisiran.  
In general, the risk of participants in this trial may be minimized by compliance with the eligibil ity criteria and study procedures, close clinical monitoring of safety parameters, as well 
as periodic review of the safety data by an independent DMC. Participants will also be observed in the clinic for at least 4 hours post injection on Day 1 and Day 360 (i.e. first dosing of 
inclisiran) and for at least 30 minutes post injection for all other dosing visits before being discharged.  

Novartis  Confidential  Page 28 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Women of child bearing potential must be informed that taking the study treatment may involve 
unknown risks to the fetus if pregnancy were to occur during the study, and agree that in order to participate in the study they must adhere to the contraception requirements outlined in the exclusion criteria. If there is any question that the participant will not reliably comply, they should not be entered or continue in the study. 
The benefit a participant might have by participating in the study is the close monitoring of their 
condition and close adherence to SoC lipid- lowering treatment.  
5 Study Population  
The study population consists of adolescents (12 to <18 years) with a genetic and/or clinical diagnosis of HeFH and LDL -C >130 mg/dL (3.4 mmol/L) on optimal SoC lipid -lowering 
therapy. 
A minimum of 102 participants (actual expected number of participants: approximately 130 ) 
meeting the eligibil ity criteria  will be randomized. 
5.1 Inclusion criteria  
Participants eligible for inclusion in this study must meet all of the following criteria:  
1. Written informed consent must be obtained from the participant’s parent(s)/legal 
representative(s) prior to the adolescent’s participation in the study. A consent or assent may also be required for some participants depending on their age and local require ments. An 
informed consent must be obtained from participants once they reach the local legal age of adulthood during the study.  
2. Male or female participants, ≥12 to <18 years of age at screening 
3. HeFH diagnosed either by genetic testing or on phenotypic criteria according to the European Atherosclerosis Society Consensus Panel (i.e. elevated LDL -C plus a family 
history of elevated LDL -C, premature coronary artery disease and/or genetic diagnosis); see 
Section  16.1  (Appendix 1) for details of the criteria including LDL -C cutoffs  
4. Fasting LDL- C >130 mg/dL (3.4 mmol/L) at the screening visit, measured at the central 
laboratory  
5. Fasting triglycerides <400 mg/dL (4.5 mmol/L) at the screening visit, measured at the 
central laboratory  
6. On maximally tolerated dose of statin (investigator’s discretion) with or without other lipid -
lowering therapy (e.g. ezetimibe). Maximum tolerated dose of statin is defined as the 
maximum dose of statin that, at the investigator’s discretion, can be taken on a regular basis without AEs that would lead to a reduction in statin dose 
7. Participants on lipid -lowering therapies (such as statin and/or e.g. ezetimibe) should be on 
a stable dose for ≥ 30 days before screening with no planned medication or dose changes during study participation 
8. Participants on a documented regimen of LDL -apheresis will be allowed to continue the 
apheresis during the study, if needed. The apheresis schedule is not allowed to change during the double -blind period of the trial and must permit that an apheresis coinc ides with 
each study visit  
Novartis  Confidential  Page 29 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
9. Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2 at screening   
10. Willing to follow all study procedures including adherence to study visits, fasting blood 
draws, and compliance with study treatment regimens  
5.2 Exclusion criteria 
Participants meeting any of the following criteria are not eligible for inclusion in this study.  
1. Previous treatment (within 90 days of screening) with monoclonal antibodies directed 
towards PCSK9  
2. (i) Active liver disease defined as any known current infectious, neoplastic, or metabolic 
pathology of the liver or (ii) unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST) elevation >3x ULN, or total bilirubin elevation >2x ULN (except patients with Gilbert’s syndrome) at screening confirmed by a repeat measurement at least 1 week apart  
3. Females who are pregnant or nursing, or who are of child- bearing potential, defined as all 
women physiologically capable of becoming pregnant (e.g. are menarchal) unless  they 
agree to abstinence or, if sexually active, agree to the use of effective methods of contraception during dosing of study treatment. Female participants of child -bearing 
potential, who are or might become sexually active, must be informed of the need to prevent 
pregnancy during the study. The effective contraception methods are: 
• Barrier method: Condom or Occlusive cap (e.g. diaphragm or cervical/vault caps). For UK sites only (if applicable): with spermicidal foam/gel/film/cream/ vaginal suppository 
• Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception 
• The decision on the contraceptive method should be reviewed at least every 3 months to evaluate the individual need and compatibility of the method chosen 
• If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form (ICF)  
• Adolescent females who have not reached menarche are exempt from the above requirements; however, to be eligible for inclusion in the study, they must be willing to comply with the above requirements if they gain child -bearing potential during the 
study 
4. Any uncontrolled or serious disease, or any medical or surgical condition, that may either 
interfere with participation in the clinical study, and/or put the participant at significant risk 
(according to investigator's [or delegate's] judgment) if he/she participates in the clinical 
study 
5. An underlying known disease, or surgical, physical, or medical condition that, in the opinion 
of the investigator (or delegate) might interfere with interpretation of the clinical study 
results  
6. Homozygous FH 
Novartis  Confidential  Page 30 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
7. Any condition that according to the investigator could interfere with the conduct of the 
study, such as but not limited to: 
• Participants who are unable to communicate or to cooperate with the investigator  
• Unlikely to comply with the protocol requirements, instructions, and study- related 
restrictions (eg, uncooperative attitude, inability to return for follow -up visits, and 
improbability of completing the study) 
• Have any medical or surgical condition, which in the opinion of the investigator would put the participant at increased risk from participating in the study  
• Persons directly involved in the conduct of the study 
8. Treatment with other investigational medicinal products or devices within 30 days or five half-lives, whichever is longer 
9. Planned use of other investigational products or devices during the course of the study 
10. Hypersensitivity to any of the ingredients of inclisiran  
11. Known history of alcohol and/or drug abuse 
12. Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome 
13. Major adverse cardiovascular events within 3 months prior to randomization  
14. Severe concomitant non -cardiovascular disease that carries the risk of reducing life 
expectancy to less than 2 years  
15. History of malignancy that required surgery (excluding local and wide -local excision), 
radiation therapy and/or systemic therapy during the 3 years prior to randomization  
16. Poorly controlled diabetes mellitus (i.e. hemoglobin A1c (HbA
1c) >10.0 %) 
17. Previous participation in this study 
6 Treatment 
6.1 Study treatment  
Participants will be randomized 2:1 to double -blind s.c. injections of inclisiran sodium 300 mg 
or placebo in Part 1 (Year 1) of the study, and subsequently all participants will receive open -
label s.c. injections of inclisiran sodium 300 mg in Part 2 (Yea r 2) of the study. 
Investigational and control drugs will not be dispensed to the participants but administered by qualified personnel at the study site. 
6.1.1 Investigational and control drugs 
The sponsor will provide the following investigational and control drugs as single -use pre -filled 
syringes for s.c. injection ( Table 6 -1). 
Part 1 (Year 1) including “Switch” Day 360:  
• Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution 
• Placebo formulation to this active drug formulation  
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection). 
Placebo will be administered as a 1.5 mL s.c. injection to match the dose in the inclisiran arm.  
Novartis  Confidential  Page 31 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
The placebo pre -filled syringes will be blinded and look identical to the corresponding inclisiran 
pre-filled syringes.  
Part 2 (Year 2):  
• Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution 
Table 6-1 Investigational and control drug  
Investigational/ 
Control Drug  Pharmaceutical 
Dosage Form  Route of 
Administration  Supply Type  Sponsor (global 
or local)  
Inclisiran sodium 
300 mg (equivalent to 284 mg inclisiran
*) in 1.5 
mL solution  Solution for 
injection  Subcutaneous injection  Solution for 
injection in pre- filled 
syringe Sponsor (global)  
Placebo  Solution for 
injection  Subcutaneous injection  Solution for 
injection in pre- filled 
syringe  Sponsor (global)  
* Inclisiran is also referred to as KJX839  
6.1.2 Additional study treatments 
No other treatment beyond investigational drug and control drug are included in this trial. 
6.1.3 Treatment arms/group 
Part 1 (Year 1):  
Participants will be assigned at the baseline/randomization visit (Day 1) to one of the following 
two double-blind treatment groups in a 2:1 ratio: 
• Inclisiran sodium 300 mg s.c. 
• Corresponding placebo 
Each participant will receive one injection of blinded inclisiran or placebo on Day 1, a second 
injection of blinded inclisiran or placebo on Day 90 and a subsequent injection of blinded inclisiran or placebo on Day 270 (“6 months dosing”). 
Part 2 (Year 2):  
Following a “Switch” Day (Day 360), all participants will receive the same active open -label 
inclisiran treatment:  
• Inclisiran sodium 300 mg s.c. 
Participants randomized to placebo in Part 1 will receive inclisiran sodium 300 mg s.c. starting 
on Day 360 (“Switch” Day 360). Participants randomized to inclisiran in Part 1 will receive placebo on Day 360. This dose of inclisiran/placebo on Day 360 will  remain blinded in order 
to maintain the blind for Part 1 of the study. 
All participants will receive subsequent doses of open- label inclisiran sodium 300 mg s.c. on 
Days 450 and 630. 
Novartis  Confidential  Page 32 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
6.1.4 Treatment duration 
The expected duration of the participant’s involvement in the study will be approximately 748 
days, which includes a screening/run -in period (28 days) and subsequent treatment with study 
drug (1 year double -blind, placebo -controlled followed by 1 year open- label follow -up), with 
the EOS visit on Day 720 (Year 2). In addition, a safety follow -up call will be conducted 30 
days after the last study visit or 90 days after the last administration of study drug, whatever is longer. 
Participants may be discontinued from treatment earlier due to safety reasons and/or at the 
discretion of the investigator or the participant’s parent(s)/legal representative(s) / participant (if applicable). They will continue to be followed up in the study unless informed consent is withdrawn ( Section  9.1.1 and Section  9.1.2).  
Participants who complete participation in this trial and continue to derive clinical benefit from the treatment based on the investigator’s evaluation may receive post- trial access (see 
Section  9.2). 
6.2 Other treatment(s)  
6.2.1 Concomitant therapy 
Concomitant lipid- lowering therapy 
Investigational and control drug will be given in addition to stable, individualized, optimal SoC for HeFH patients, which includes maximally tolerated dose of statin (investigator’s discretion) with or without other lipid -lowering therapy (e.g. ezetimibe) . Maximum tolerated dose of statin 
is defined as the maximum dose of statin that, at the investigator’s discretion, can be taken on a regular basis without AEs that would lead to a reduction in statin dose. Intolerance to statin must be documented as medic al history attributed to the statin in question in the source 
documentation and on an appropriate Electronic Case Report Form (eCRF). 
Participants are required to maintain their current lipid -lowering treatment unchanged for Part 
1 (Year 1) of the study, including the screening/run- in period (i.e. no medication or dose 
changes; see also Section  6.2.2). Lipid -lowering medications taken by the participant from 3 
months prior to randomization through the End of the Study must be recorded, including doses, 
on an appropriate eCRF. 
Participants on a documented regimen of LDL -apheresis will be allowed to continue their same 
regimen during the study, if needed. The apheresis schedule is not allowed to change during 
Part 1 (Year 1) of the study (including the screening/run -in period). T he apheresis schedule 
must also allow that an apheresis coincides with each study visit. Study drug is to be 
administered the same day, after completion of apheresis (the next scheduled apheresis should not occur within 72 hours after an administration of study drug). Blood samples for LDL -C (and 
other laboratory assessments of efficacy and safety) must be obtained immediately before the scheduled apheresis treatment at each applicable study visit (including screening and baseline (Day 1)). LDL -apheresis, w hich the participant receives from 2 months prior to randomization 
through the End of the Study, must be recorded on an appropriate eCRF. 
Novartis  Confidential  Page 33 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Other concomitant therapy  
All other medications, procedures and significant non-drug therapies used by the participant in 
the 3 months prior to randomization must be recorded on the appropriate eCRFs, independent of whether they will be continued during the study or not. Each conco mitant drug must be 
individually assessed against all exclusion criteria.  
All other medications, procedures and significant non -drug therapies (including physical 
therapy and blood transfusions) administered after the participant was enrolled into the study must also be recorded on appropriate eCRF pages. A new concomitant drug must be assessed against all prohibited medications prior to its initiation.  
If in doubt the investigator should contact the Novartis medical monitor before randomizing a participant or allowing a new medication to be started. If the participant is already enrolled, contact Novartis to determine if the participant should continue s tudy medication. 
6.2.2 Prohibited medication 
Participants need to be on stable background lipid- lowering therapy for Part 1 (Year 1) of the 
study (including the screening/run- in period), i.e. the type and dose of lipid- lowering therapy 
must not be altered during this time. Use of the treatments displayed in Part A of Table 6 -2 
below are therefore not allowed to be newly added at any time during Part 1 (Year 1) of the study, including the screening/run-in period. 
In addition, use of the treatments displayed in Part B of Table 6 -2 below are not allowed at any 
time during the entire study duration. 
Table 6-2 Prohibited medication  
Medication Prohibition period  Action taken with study 
treatment  
PART A: Medications not allowed to be newly added during Part 1 (Year 1)  of the study  
Medications* prescribed to lower 
LDL-C (e.g., statins, ezetimibe, lomitapide, mipomersen, niacin, 
colesevelam, bile acid absorption inhibitors, LDL- apheresis)  
*For monoclonal antibodies 
directed towards PCSK9, see Part 
B Part 1 (Year 1) of the study 
(including screening/run- in period)  None  
Any medication taken for the 
purpose of lipid -lowering, including 
over-the-counter or herbal 
therapies   Part 1 (Year 1) of the study 
(including screening/run- in period)  None  
PART B: Regular prohibited medications  
Monoclonal antibodies directed 
towards PCSK9  Full Study Duration  Discontinue study treatment  
Other investigational treatments  Full Study Duration  Discontinue study treatment   
Novartis  Confidential  Page 34 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
6.3 Participant numbering, treatment assignment, randomization 
6.3.1 Participant numbering 
Each participant is identified in the study by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening and is retained for the participant throughout his/her entire participation in the trial. The Participant  No. consists of the Center 
Number (Center No.) (as assigned by Novartis to the investigative site) with a sequential participant number suffixed to it, so that each participant’s participation is numbered uniquely across the entire database. Upon the part icipant’s parent(s)/legal representative(s) / participant 
(if applicable) signing the ICF, the participant is assigned to the next sequential Participant No. available.  
6.3.2 Treatment assignment, randomization  
At the baseline/randomization visit (Day 1), all eligible participants will be randomized via Interactive Response Technology (IRT) to one of the treatment arms. The investigator or his/her delegate will contact the IRT after confirming that the participant fulfills all the inclusion/exclusion criteria. The IRT will assign a randomization number to the participant, which will be used to link the participant to a treatment arm and will specify a unique medication number for the first package of study treatme nt to be dispensed to the participant. 
The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from participants and investigator staff. A participant randomization list will be produced by the IRT provider using a validated system that automates the random assignment of participant numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers. A separate medication list will b e produced by or under the responsibility 
of Novartis Global Clinical Supply using a validated system that automates the random assignment of medication numbers to packs containing the study treatment. 
Randomization will be stratified by age (≥12 to <15 years and ≥15 to <18 years, to include a 
minimum of 40 participants in each of the two age strata).  
The randomization scheme for participants will be reviewed and approved by a member of the Randomization Office.  
6.4 Treatment blinding  
Part 1 (Year 1)  
Part 1 of the study is randomized, double -blind and placebo -controlled. Participants, 
investigator staff, persons performing the assessments, and the clinical trial team (CTT) will remain blind to the identity of the treatment from the time of randomizatio n until at least 
database lock for all Part 1 (Year 1) data, using the following methods: (1) Randomization data are kept strictly confidential until the time of unblinding, and will not be accessible by anyone else involved in the study with the following exceptions: the independent statistician and 
programmer who need to have access to prepare interim analysis reports for the DMC and the 
 

Novartis  Confidential  Page 35 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
 
     
 
  
 
  
 
 
 
Unblinding will occur in the case of participant emergencies and at the conclusion of the study. Unblinding of the CTT and other parties (as needed) will also occur after the Year 1 database lock, which is planned after all participants have completed the Day 360 visit. 
Part 2 (Year 2)  
Due to the single -arm, open- label design, treatment in Part 2 of the study will be open to 
participants, investigator staff, persons performing the assessments, and the CTT.  
In order to maintain the blind for Part 1 of the study, on the “switch” day (Day 360), participants 
randomized to placebo in Part 1 will receive blinded inclisiran, while participants randomized 
to inclisiran in Part 1 will receive blinded placebo.  
6.5 Dose escalation and dose modification  
Dose adjustments of study treatment are not permitted.  
6.5.1 Dose modifications  
Dosing with study treatment should be temporarily interrupted as follows:  
Part 1 (Year 1):  
• If from the Day 150 visit onwards a participant’s LDL -C is below 25 mg/dL ( 0.65 mmol/L) 
at the last visit prior to the time of the next scheduled dose, the IRT will assign blinded 
placebo to be administered at the next scheduled dosing visit independent of which treatment group the participant was randomized to; i.e. if the participa nt was treated with 
inclisiran, study treatment will be interrupted in a blinded fashion via the IRT.  
Part 2 (Year 2):  
• If from the Day 450 visit onwards a participant’s LDL -C is below 25 mg/dL ( 0.65 mmol/L) 
at the last visit prior to the time of the next scheduled dose, the investigator should withhold 

Novartis  Confidential  Page 36 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
the dose at the next scheduled dosing visit. This will be flagged accordingly by the central 
laboratory. 
• These dose interruptions must be recorded on an appropriate eCRF. 
Treatment discontinuation is mandatory for specific events listed in Section  9.1.1. 
6.5.2 Follow -up for toxicities 
6.5.2.1 Follow up on potential drug- induced liver injury (DILI) cases 
Participants with transaminase increase combined with total bilirubin increase may be 
indicative of potentially severe DILI, and should be considered as clinically important events 
and assessed appropriately to establish the diagnosis. The required clinica l information, as 
detailed below, should be sought to obtain the medical diagnosis of the most likely cause of the observed laboratory abnormalities.  
The threshold for potential DILI may depend on the participant’s baseline AST/ALT and total bilirubin value; participants meeting any of the following criteria will require further follow -up 
as outlined below: 
• For participants with normal ALT and AST and total bilirubin value at baseline: AST or 
ALT >3.0x ULN combined with total bilirubin >2.0x ULN 
• For participants with elevated AST or ALT or total bilirubin value at baseline: [AST or ALT >2.0x baseline] OR [AST or ALT >300 U/L] whichever occurs first combined with [total bilirubin >2.0x baseline AND >2.0x ULN] 
As DILI is essentially a diagnosis of exclusion, other causes of abnormal liver tests should be considered and their role clarified before DILI is assumed as the cause of liver injury.  
A detailed history, including relevant information such as review of ethanol consumption, concomitant medications, herbal remedies, supplement consumption, history of any pre -
existing liver conditions or risk factors, should be collected. 
Laboratory tests should include ALT, AST, total bilirubin, direct and indirect bilirubin, gamma -
glutamyl transferase (GGT), glutamate dehydrogenase (GLDH), prothrombin time 
(PT)/International Normalized Ratio (INR), alkaline phosphatase (ALP), albumin, and creatine 
(phospho)kinase (C(P)K). 
Perform relevant examinations (Ultrasound or Magnetic resonance imaging (MRI), Endoscopic 
retrograde cholangiopancreatography (ERCP)) as appropriate, to rule out an extrahepatic cause of cholestasis. Cholestasis (is defined as an ALP elevation >2.0x ULN wi th R value < 2 in 
participants without bone metastasis, or elevation of the liver- specific ALP isoenzyme in 
participants with bone metastasis).  
Note: The R value is calculated by dividing the ALT by the ALP, using multiples of the ULN for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R > 2 and < 5) liver injury. For children, 
there are caveats to calculating the R -ratio as normal levels of ALP are higher than in adults 
with standard ranges varying by developmental age. In clinical situations where it is suspected that ALP elevations are from an extra hepatic source, the GGT can be used if available. GGT 
may be less specific than ALP as a marker of cholestatic injury, since GGT can also be elevated 
Novartis  Confidential  Page 37 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
by enzyme induction or by ethanol consumption. It is more sensitive than ALP for detecting 
bile duct injury. 
Table 6 -3 provides guidance on specific clinical and diagnostic assessments which can be 
performed to rule out possible alternative causes of observed liver function test (LFT) 
abnormalities.  
Table 6-3 Guidance on specific clinical and diagnostic assessments which can 
be performed to rule out possible alternative causes of observed LFT 
abnormalities 
Disease  Assessment  
Hepatitis A, B, C, E  • IgM anti -HAV; HBsAg, IgM & IgG anti -HBc, HBV DNA; anti -HCV, HCV 
RNA, IgM & IgG anti-HEV, HEV RNA  
CMV, HSV, EBV infection  • IgM & IgG anti -CMV, IgM & IgG anti -HSV; IgM & IgG anti -EBV 
Autoimmune hepatitis  • ANA & ASMA titers, total IgM, IgG, IgE, IgA  
Alcoholic hepatitis  • Ethanol history, GGT, MCV, CD -transferrin  
Nonalcoholic steatohepatitis  • Ultrasound or MRI  
Hypoxic/ischemic hepatopathy  • Medical history: acute or chronic CHF, hypotension, hypoxia, hepatic 
venous occlusion. Ultrasound or MRI.  
Biliary tract disease  • Ultrasound or MRI, ERCP as appropriate  
Wilson disease (if <40 yrs old)  • Ceruloplasmin  
Hemochromatosis  • Ferritin, transferrin  
Alpha-1-antitrypsin deficiency  • Alpha -1-antitrypsin  
ANA (antinuclear antibody), ASMA (anti -smooth muscle antibody), CD (carbohydrate- deficient), CHF (chronic 
heart failure), CMV (cytomegalovirus), EBV (Epstein -Barr virus), ERCP (Endoscopic retrograde 
cholangiopancreatography), HAV (hepatitis A virus), HBc ( hepatitis B core), HBsAG (HBV surface antigen), 
HBV (hepatitis B virus), HCV (hepatitis C virus), HEV (hepatitis E virus), HSV (herpes simplex virus), Ig 
(Immunoglobulin), MCV (mean corpuscular volume), MRI (Magnetic Resonance Imaging)  
Other causes should also be considered based upon participants’ medical history 
(hyperthyroidism / thyrotoxic hepatitis – T3, T4, thyroid stimulating hormone (TSH); CVD / 
ischemic hepatitis – ECG, prior hypotensive episodes; type 1 diabetes / glycogenic hepatitis). 
In addition to the causes listed in Table 6 -3, metabolic disorders should be excluded in children 
by measuring the following parameters: urinary ketones, ammonia, glucose, lactate, 
lactate:pyruvate ratio, alpha fetoprotein, arterial blood gas analysis.  
Following appropriate causality assessments, as outlined above, the causality of the treatment is estimated as “probable” i.e. >50% likely, if it appears greater than all other possible causes of liver injury combined. The term “treatment- induced” indicate s probably caused by the 
treatment, not by something else, and only such a case can be considered a DILI case and should be reported as an SAE.  
All cases confirmed on repeat testing meeting the laboratory criteria defined above, with no other alternative cause for LFT abnormalities identified, should be considered as “medically significant,” and thus, meet the definition of SAE and should be repor ted as SAE using the term 
“potential treatment -induced liver injury.” All events should be followed up with the outcome 
clearly documented. 
Novartis  Confidential  Page 38 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
6.6 Additional treatment guidance  
6.6.1 Treatment compliance 
The investigator must promote compliance by informing the participant that compliance is 
necessary for the participant’s safety and the validity of the study. The investigator should also instruct the participant to adhere closely to the scheduled study vi sits. Study treatment will not 
be dispensed to the participant but will be administered at designated study visits at the study site by qualified personnel, facilitating compliance. Study drug dosing information should be captured within each designated visit on an appropriate eCRF. The investigator or designee must also maintain an inventory record of study drug (inclisiran/placebo) received and administered.  
 
  
6.6.2 Recommended treatment of adverse events 
Adverse events should be treated according to local practice and guidelines, and is at the discretion of the investigator and treating physician. 
For participants with injection site reaction, antihistamines, local or systemic steroids can be 
used at the investigator’s discretion depending on the severity of the reaction. 
Medication used to treat AEs must be recorded on appropriate eCRF page(s).  
6.6.3 Emergency breaking of assigned treatment code 
Emergency code breaks must only be undertaken when it is required to in order to treat the 
participant safely. Blinding codes may also be broken after a participant discontinues treatment due to disease progression if deemed essential to allow the investig ator to select the participant’s 
next treatment regimen, and after discussion and agreement with the sponsor. Most often, study treatment discontinuation and knowledge of the possible treatment assignments are sufficient to treat a study participant who presents with an emergency condition. Emergency treatment code breaks are performed using the IRT. When the investigator contacts the system to break a treatment code for a participant, he/she must provide the requested participant identifying information and confirm the necessity to break the treatment code for the participant. The investigator will then receive details of the investigational drug treatment for the specified participant and a fax or email confirming this information. The system will automatically inform the Novartis monitor for the site and the study team that the code has been broken. 
It is the investigator’s responsibility to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency. The investigator will provide: 
• protocol number 
• name 
• participant number  

Novartis  Confidential  Page 39 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
In addition, oral and written information to the participant must be provided on how to contact 
his/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at any time.  
After an emergency un -blinding, study drug should be permanently discontinued. The 
participant will continue to be followed up in the study unless informed consent is withdrawn (Section  9.1.1 and Section  9.1.2).  
6.7 Preparation and dispensation  
Each study site will be supplied with study drug in packaging as described under investigational and control drugs section. 
A unique medication number is printed on the study medication label.  Investigator staff will identify the study medication kits to administer to the participant by 
contacting the IRT and obtaining the medication number(s). The study medication has a 2- part 
label (base plus tear -off label); immediately before using the medication kit, site personnel will 
detach the outer part of the label from the packaging and affix it to the source document. 
6.7.1 Handling of study treatment and additional treatment  
6.7.1.1 Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, all study treatment must be stored according to the instructions specified on the labels.  
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints are to be reported to the respective Novartis Country Organization Quality Assurance. 
Medication labels will be in the local language and comply with the legal requirements of each 
country. They will include storage conditions for the study treatment but no information about the participant except for the medication number . 
The investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by monitors during site visits or remotely and at the completion of the trial.  
At the conclusion of the study, and as appropriate during the course of the study, the investigator will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.  
6.7.2 Instruction for prescribing and taking study treatment  
Investigational and control drugs will not be dispensed to the participants. Study drug injections 
will be performed exclusively at the study site by qualified clinical study site staff under the supervision of the investigator or designee. 
Novartis  Confidential  Page 40 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
The site of injection is the abdomen, alternating sides for each injection. Injections should not 
be done into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, tattoos or skin infections. 
Participants will be administered one s.c. injection of study drug at pre -defined visits as 
specified in the Assessment Schedule ( Table 8 -1) and summarized below. 
• Part 1:  Each participant will receive one injection of blinded inclisiran or placebo on Day 
1, a second injection of blinded inclisiran or placebo on Day 90 and a subsequent injection 
of blinded inclisiran or placebo on Day 270 (“6 months dosing”). 
• Part 2:  Participants randomized to placebo in Part 1 will receive a single injection of blinded 
inclisiran on Day 360, while participants randomized to inclisiran in Part 1 will receive a 
single injection of blinded placebo on Day 360. All participants will receive subsequent doses of open-label inclisiran on Day 450 and Day 630. 
Injections will be administered after all other study assessments have been completed for the visit. At the Randomization (Day 1) and Day 360 visits, vital signs (blood pressure and pulse) and ADA (Day 1 only) will be assessed a second time 4 hours after i njection.  
P
articipants must be observed in the clinic for at least 4 hours post injection on Day 1 and Day 
360 (i.e. first dosing of inclisiran) and for at least 30 minutes post injection for all other dosing visits before being discharged. 
Should a participant develop signs or symptoms of anaphylaxis when study drug is injected, the 
investigator will need to collect a blood sample for tryptase within 30 minutes of the onset of anaphylaxis (or as soon as possible). 
All kits of study treatment assigned by the IRT will be recorded in the IRT system.  
All injections to the participant as well as study drug interruptions/discontinuations (i.e. no 
injection at a designated dosing visit) during the study must be recorded on an appropriate eCRF.  
7 Informed consent procedures  
Eligible participants may only be included in the study after the participant’s parent(s)/legal representative(s) or the participant (if applicable) provides (witnessed, where required by law or regulation), Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent. 
In cases where the participant's parent(s)/legal representative(s) give consent, the participant 
must be informed about the study to the extent possible given his/her understanding. If the participant is capable of doing so, he/she should indicate assent by personally signing and dating the written informed consent document or a separate assent form (as per local requirements). An informed consent must be obtained from the participant once he/she reaches the local legal age of adulthood during the study. 

Novartis  Confidential  Page 41 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Informed consent must be obtained before conducting any study- specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent and 
participant assent where applicable must be documented in the participant’s source documents. 
Novartis will provide to investigators in separate documents proposed ICF(s) and age 
appropriate assent form(s) that comply with the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and regulatory requirements and are c onsidered 
appropriate for this study. Any changes to the proposed consent/assent forms suggested by the investigator must be agreed by Novartis before submission to the IRB/IEC.  
Information about common side effects already known about the investigational drug can be found in the IB. This information will be included in the informed consent and should be discussed with the participant’s parent(s)/legal representative(s) and, to the extent possible, the participant during the study as needed. Any new information regarding the safety profile of the investigational drug that is identified between IB updates will be communicated as appropriate, 
for example, via an investigator notification or an aggregate safety finding. New information might require an update to the informed consent/assent and then must be discussed with the participant’s parent(s)/legal representative(s) and, to the extent possible, the participant. 
Women of child bearing potential and her parent(s)/legal representative(s) must be informed 
that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study they must adhere to the contraception requirements. 
  
 
    
 
A copy of the approved version of all consent/assent forms must be provided to Novartis after IRB/IEC approval.  
8 Visit schedule and assessments 
The Assessment Schedule ( Table 8 -1) lists all of the assessments when they are performed. All 
data obtained from these assessments must be supported in the participant’s source documentation. 
Participants should be seen for all visits/assessments as outlined in the Assessment Schedule or 
as close to the designated day/time as possible. Missed or rescheduled visits should not lead to automatic discontinuation.  
Participants who prematurely and permanently discontinue from study treatment will continue to be followed up in the study according to the Assessment Schedule unless informed consent 
is withdrawn. 

Novartis  Confidential  Page 42 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Participants who prematurely discontinue the study for any reason [e.g. if a participant’s 
parent(s)/legal representative(s) / a participant (if applicable) decide to prematurely and permanently discontinue the participant from study treatment and decline further follow -up 
visits] should be scheduled for an EOS visit as soon as possible. At this final visit, AEs and concomitant medications should be recorded in the corresponding eCRFs. 
Participants will have to comply with the following restrictions:  
• Participants should have fasted for at least 8 hours for all visits for fasting 
lipids/lipoproteins/PCSK9 and glucose blood samples (if the participant has not fasted, the 
collection of laboratory evaluations must be rescheduled) 
• Participants must refrain from unaccustomed strenuous physical exercise for 48 hours before the screening and any study visit until the follow-up has been completed 
• Blood donation will not be allowed at any time during the study 
If an extraordinary situation (like e.g. during the coronavirus disease (COVID) -19 pandemic) 
limits or prevents on -site study visits, alternative methods of providing continuing care may be 
implemented. Phone calls, virtual contacts (e.g. teleconsult) or visits by site staff / home nursing service to the participant´s home depending on local regulations and capabilities, can replace on-site study visits, for the duration of the extraordinary situation until it is safe for the 
participant to visit the site a gain. This also includes administration of study treatment by 
qualified study site personnel at a location other than the study site . 
Novartis   Confidential   Page 43 of 90 
Amended Protocol  Version 02 ( Clean )    Protocol No. CKJX839C12301  
 
Table 8-1 Assessment Schedule 
Period  Screening1 Part 1 (Double -blind, placebo -controlled)  Part 2 (Open -label, single -arm)  Follow -up 
Visit Name  Screening  Day 1 
(Baseline 
& 1st 
Treatment)  Day 30  Day 90  Day 150  Day 270  Day 330  Day 360 
("Switch 
Day")2 Day 450  Day 510  Day 630  Day 720 
(End of 
Treatment/ 
Study)3 Safety 
follow-up 
(last visit 
+30 days)4 
Days  -28 1 30 90 150 270 330 360 450 510 630 720 750 
Informed consent / 
assent (as applicable)  X             
Inclusion / Exclusion 
criteria  X             
Demography  X             
Pregnancy Test 
(serum)5 X             
Pregnancy test 
(urine)5  S      S    S  
Relevant medical 
history/current 
medical conditions  X             
Medical history Statin intolerance (if 
applicable)  X             
Smoking & Alcohol 
history  X             
Body weight / waist 
circumference  X X X X X X X X X X X X  
Body Height  X X   X  X   X  X  
Vital Signs6 X X X X X X X X X X X X  
Physical Exam 
(complete)  S      S     S  
Physical Exam 
(abbreviated)   S S S S S  S S S S   
Novartis   Confidential   Page 44 of 90 
Amended Protocol  Version 02 ( Clean )    Protocol No. CKJX839C12301  
 
Period  Screening1 Part 1 (Double -blind, placebo -controlled)  Part 2 (Open -label, single -arm)  Follow -up 
Visit Name  Screening  Day 1 
(Baseline 
& 1st 
Treatment)  Day 30  Day 90  Day 150  Day 270  Day 330  Day 360 
("Switch 
Day")2 Day 450  Day 510  Day 630  Day 720 
(End of 
Treatment/ 
Study)3 Safety 
follow-up 
(last visit 
+30 days)4 
Days  -28 1 30 90 150 270 330 360 450 510 630 720 750 
12-lead ECG  X      X     X  
Study drug 
administration7,8  X  X  X  X X  X   
IRT call  X X X X X X X X X X X X  
Prior/Concomitant 
lipid-lowering therapy  X X X X X X X X X X X X  
(Other) 
Prior/Concomitant 
Medications  X X X X X X X X X X X X  
Surgical/Medical 
Procedures  X X X X X X X X X X X X  
LDL- apheresis 
recording (if 
applicable)  X X X X X X X X X X X X  
Fasting LDL -C X X  X X X X X X X X X  
Fasting PCSK9   X  X X  X X  X  X  
Full fasting lipid / 
lipoprotein profile9  X   X  X X  X  X  
Anti-drug antibodies10  X   X  X   X  X  
Full chemistry11  X     X     X  
Limited chemistry11 X  X X X X  X X X X   
Hematology  X X X  X  X  X X  X  
Sexual hormones   X     X     X  
Urinalysis  X X X  X  X  X X  X  
AEs/SAEs  X X X X X X X X X X X X  
Injection site reaction 
assessment   X X X X X X X X X X X  
Novartis   Confidential   Page 45 of 90 
Amended Protocol  Version 02 ( Clean )    Protocol No. CKJX839C12301  
 
Period  Screening1 Part 1 (Double -blind, placebo -controlled)  Part 2 (Open -label, single -arm)  Follow -up 
Visit Name  Screening  Day 1 
(Baseline 
& 1st 
Treatment)  Day 30  Day 90  Day 150  Day 270  Day 330  Day 360 
("Switch 
Day")2 Day 450  Day 510  Day 630  Day 720 
(End of 
Treatment/ 
Study)3 Safety 
follow-up 
(last visit 
+30 days)4 
Days  -28 1 30 90 150 270 330 360 450 510 630 720 750 
Neurological 
Examination   X     X     X  
Tanner staging / 
menarche   X   X  X   X  X  
Safety Follow up 
Call14             S 
X Assessment to be recorded in the clinical database or received electronically from a vendor  
S Assessment to be recorded in the source documentation only  
1 Screening / run-in period  
2 Day 360 (“Switch Day”) is a shared visit, i.e. the end of Part 1 and the start of Part 2 of the study  
3 For participants who prematurely discontinue the study for any reason [e.g. if a participant’s parent(s)/legal representative(s) / a participant (if applicable) decide to 
prematurely and permanently discontinue the participant from study treatment and decline further follow -up visits] an EOS visit should also be scheduled as soon as 
possible.  
4 30 days after the last study visit or 90 days after the last  administration of study drug, whatever is longer  
5 Only in females of child- bearing potential (prior to study treatment administration, if applicable)  
6 On Day 1 and Day 360 vital signs will be measured prior to injection and 4 hours post injection; at all other visits, vital signs will be measured only once (prior to 
injection, if applicable).  
7 Participants will be observed in the clinic for at least 4 hours post injection on Day 1 and Day 360 and for at least 30 minutes post injection for all other dosing visits.  
8 For any suspected episode of anaphylaxis, the investigator will need to collect a blood sample for tryptase within 30 minutes  of an onset of anaphylaxis (or as soon as 
possible).  
9 Apo B, Lp(a), non -HDL-C, total cholesterol, triglycerides, HDL -C, VLDL -C and Apo A1 in addition to the separately listed LDL -C (see Section 8.3  for details).  

Novartis   Confidential   Page 46 of 90 
Amended Protocol  Version 02 ( Clean )    Protocol No. CKJX839C12301  
 
Period  Screening1 Part 1 (Double -blind, placebo -controlled)  Part 2 (Open -label, single -arm)  Follow -up 
Visit Name  Screening  Day 1 
(Baseline 
& 1st 
Treatment)  Day 30  Day 90  Day 150  Day 270  Day 330  Day 360 
("Switch 
Day")2 Day 450  Day 510  Day 630  Day 720 
(End of 
Treatment/ 
Study)3 Safety 
follow-up 
(last visit 
+30 days)4 
Days  -28 1 30 90 150 270 330 360 450 510 630 720 750 
10 ADA serum samples will be collected on Day 1 prior to injection and 4 hours after injection. At all other visits, one sample only will be collected.  
11 Diagnosis of diabetes based on fasting plasma glucose (FPG) should be verified by a repeat FPG within 6 weeks of the initial observation  
 
 
14 SAEs to be reported to Novartis Safety (see Section 10.1.3  for details) 
 

Novartis  Confidential  Page 47 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
8.1 Screening  
Screening activities ( Table 8 -1) must be initiated only after the ICF (and assent if applicable) 
has been signed.  
It is not permissible to re -screen a participant if s/he fails the initial screening. In the case where 
a safety laboratory assessment at screening is outside of the range specified in the exclusion 
criteria, the assessment may be repeated once prior to randomization. If the repeat value remains outside of the specified ranges, the participant is not eligible for the study. 
8.1.1 Information to be collected on screening failures  
Participants for whom an ICF was signed and who are subsequently found to be ineligible prior 
to randomization will be considered a screen failure. The reason for screen failure should be recorded on an appropriate eCRF. The demographic information, informed consent, and inclusion/exclusion pages must also be completed for screen failure participants. I f the screen 
failure participant experienced a SAE during the screening phase (see SAE section for reporting 
details) , SAE information must additionally be collected. If the participant fails to be 
randomized, the IRT must be notified within 2 days of the screen fail that the participant was not randomized. 
Participants who are randomized and fail to start treatment, e.g. participants randomized in 
error, will be considered an early terminator. The reason for early termination should be recorded on an appropriate eCRF. 
8.2 Participant demographics/other baseline characteristics  
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with eCRF.  
Participant demographic and baseline characteristic data to be collected on all participants include: age, sex, race, ethnicity, relevant medical history/current medical condition present before informed consent was signed (where possible, diagnoses and not symptoms will be recorded), concomitant lipid- lowering therapy, as well as relevant laboratory tests.  
Investigators will have the discretion to record abnormal test findings as medical history in an appropriate eCRF whenever, in their judgment, the test abnormality occurred prior to the informed consent signature. 
8.3 Efficacy  
The efficacy assessments are specified below, with the Assessment Schedule ( Table 8 -1) 
detailing when each assessment is to be performed.  
All efficacy biomarkers will be analyzed at a Central laboratory(ies). Participants will be in a fasted state for all efficacy laboratory assessments. At dosing visits, specimens for the analysis of efficacy biomarkers must be collected prior to study drug  administration.  Details regarding 
the collection, processing, shipping and storage of the samples will be provided in a Laboratory Manual. The Laboratory Manual will also provide details about prioritization when blood volume is restrictive (Section  16.7 (Appendix 7)). 
Novartis  Confidential  Page 48 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
8.3.1 LDL-cholesterol  
The primary efficacy assessment will be LDL -C. Samples for LDL -C will be collected at 
screening and on Days 1, 90, 150, 270, 330, 360, 450, 510, 630 and 720 ( Table 8 -1). 
After randomization (Day 1) until the Day 360 visit, the results from the LDL -C laboratory 
assessments must be blinded to participants, investigator staff, persons performing the 
assessments, and the CTT.  
8.3.2 Other efficacy biomarkers 
Other efficacy assessments will include:  
• Apo B, Lp(a), non- HDL -C, total cholesterol,  triglycerides, HDL -C, VLDL -C, Apo A1, 
PCSK9  
Samples for these additional efficacy biomarkers will be collected on Days 1, 90 (PCSK9 only), 150, 330, 360, 510 and 720. ( Table 8 -1). 
After randomization (Day 1) until the Day 360 visit, the results from the efficacy laboratory assessments must be blinded to participants, investigator staff, persons performing the assessments, and the CTT.   
  
   
 
8.3.4 Appropriateness of efficacy assessments  
LDL -C reduction, which is an effect of the mechanism of action of inclisiran, is a well -defined 
biomarker and standard assessment in clinical trials, and the primary endpoint of the study. LDL -C reduction is an accepted surrogate for CV risk reduction, e.g. for statins and PCSK9-
blocking monoclonal antibodies. While multiple factors contribute to the development of ASCVD, strong and consistent evidence from genetics, epidemiology, Mendelian randomization studies, and randomized trials, have established that among these factors, LDL-C is not merely a biomarker of increased risk, but a caus al and modifiable factor in ASCVD 
(Ference et  al 2017).  
Laboratory and other assessments related to the secondary are in line 
with the expected efficacy of inclisiran. 
8.4 Safety  
Safety assessments are specified below, with the Assessment Schedule ( Table 8 -1) detailing 
when each assessment is to be performed.  
For details on AE collection and reporting, refer to the AE section. 

Novartis  Confidential  Page 49 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
A complete physical examination will be performed at the screening visit, the Day 330 visit and 
at the Study Completion (EOS) visit. An abbreviated physical examination will be performed at other study visits detailed in Table 8 -1. Details on what is included in the complete and 
abbreviated physical exams and the requirements to perform vital signs assessment and height / weight measurements are provided in Table 8 -2. 
Table 8-2 Assessments & Specifications 
Assessment  Specification  
Physical 
examination  A complete physical examination  will include the examination of height, weight, general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, vital 
signs, abdomen, back, lymph nodes, extremities, vascular, and neurological. If indicated 
based on medical history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be performed.  
Tanner staging ( Section 8.4.4.1) will additionally be performed at selected visits.  
A short physical examination  will include the examination of general appearance and 
vital signs as well as other examinations based on Investigator discretion. Height and weight will additionally be assessed as per the Schedule of Assessment.  
Information for all physical examinations must be included in the source documentation at 
the study site. Clinically relevant findings that are present prior to informed consent signature must be recorded on the appropriate eCRF that captures Medical history. 
Significant findings made after informed consent signature, which meet the definition of an 
AE, must be recorded as an AE.  
Vital signs  Vital signs include blood pressure and pulse measurements. After the participant has been 
sitting for five minutes, with back supported and both feet placed on the floor, systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be measured three times 
using an automated validated device, e.g. OMRON, with an appropriately sized cuff. The 
repeat sitting measurements will be made at 1 - 2 minute intervals and the mean of the 
three measurements will be used. In case the cuff sizes available are not  large enough for 
the participant's arm circumference, a sphygmomanometer with an appropriately sized cuff 
may be used.  
Clinically notable vital signs are defined in Section  16.2 (Appendix 2).   
Height and 
weight  Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) in indoor 
clothing, but without shoes) will be measured. Height should be taken using a calibrated 
stadiometer.  
8.4.1 Laboratory evaluations  
Specimens will be obtained at the time points detailed in the Assessment Schedule ( Table 8 -1). 
Details on what is included in hematology, chemistry, sexual hormones, and urinalysis 
laboratory evaluations are provided in Table 8 -3. Efficacy laboratory assessments (e.g. LDL -
C) are described in Section  8.3. 
Central laboratory(ies) will be used for analysis of all specimens collected, with the exception of urine pregnancy tests, which will be done locally (using testing materials supplied by the central laboratory). Serum pregnancy tests at screening will be done by the central laboratory. Details on the collections, shipment of samples and reporting of results by the central laboratory are provided to investigators in a Laboratory Manual.  
Clinically notable laboratory findings are defined in Section  16.2 (Appendix 2). 
A table, which provides the maximum, allowable blood- draw volumes by weight, can be found 
in Section  16.7 (Appendix 7). The Laboratory Manual will also provide details about 
prioritization when blood volume is restrictive.  
Novartis  Confidential  Page 50 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Table 8-3 Laboratory Assessments 
Test Category  Test Name  
Hematology  Hemoglobin, hematocrit, red blood cell (RBC) count, mean cell hemoglobin 
(MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), white blood cell (WBC) count with differential 
(neutrophils, basophils, eosinophils, monocytes, lymphocytes), platelet count  
Chemistry Full chemistry:  
AST, ALT, ALP, GGT, total bilirubin, direct and indirect bilirubin (if total bilirubin >2xULN), C(P)K, bicarbonate, uric acid, creatinine, blood urea 
nitrogen (BUN), eGFR*, sodium, potassium, calcium, phosphate, chloride, albumin, total protein, glucose (fasting)**, HbA
1C 
Limited chemistry:  
ONLY: AST, ALT, ALP, GGT, total bilirubin [fractionated bilirubin (if total 
bilirubin >2x ULN)], C(P)K, creatinine, eGFR*, glucose (fasting)**, HbA 1C 
Anti-drug antibodies  see Section  8.4.1.1  
Sexual hormones  Gonadal hormones (estradiol for females and testosterone for males), 
luteinizing hormone (LH), follicle -stimulating hormone (FSH), cortisol and 
dehydroepiandrosterone (DHEA)  
Urinalysis  Dipstick measurements for: specific gravity, pH, glucose, protein (total), ketones, bilirubin, urobilinogen, nitrite, hemoglobin (blood), leukocytes 
esterase  
If dipstick measurement results are positive (abnormal), microscopic 
examination will be performed  
Pregnancy test  Serum / Urine pregnancy test (see Section  8.4.3 )  
Other  Tryptase (only as required***)  
* eGFR will be calculated using the Schwartz age-specific eGFR formula as follows:  
• For height in cm and serum creatinine (sCr) in mg/dL: eGFR (mL/min/1.73 m2) = 0.413 x (height/sCr)  
• For height in cm and sCr in μmol/L: eGFR (mL/min/1.732) = 36.5 x (height/sCr)  
** Diagnosis of diabetes based on FPG should be verified by a repeat FPG within 6 weeks of the initial 
observation.  
*** Should a participant develop anaphylaxis on days when inclisiran is injected, the investigator will need to 
collect a blood sample for t ryptase within 30 minutes of the onset of anaphylaxis (or as soon as possible).  
8.4.1.1 Anti-drug antibodies 
Serum samples for the analysis of formation of ADA will be collected at the time points detailed 
in the Assessment Schedule ( Table 8 -1). 
On Day 1, ADA serum samples will be collected prior to injection and 4 hours after injection. At all other visits, one sample only will be collected.  
The results from ADA after the first administration of study drug until the Day 360 visit must be blinded to participants, investigator staff, persons performing the assessments, and the CTT. 
Instructions to be followed regarding sample collection, numbering, processing and shipment 
are outlined in a Laboratory Manual. 
8.4.2 Electrocardiogram (ECG)  
ECGs will be done with local ECG machines. ECGs must be recorded (after 10 minutes rest in 
the supine position to ensure a stable baseline). The preferred sequence of CV data collection during study visits is ECG collection first, followed by vital signs, and blood sampling. The Fridericia QT correction formula (QTcF) should be used for clinical decisions.  
Novartis  Confidential  Page 51 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Single 12 lead ECGs are collected. The original ECGs on non- heat-sensitive paper and a copy 
(if original ECG done on heat sensitive paper), appropriately signed, must be collected and 
archived at the study site.  
For any ECGs with participant safety concerns, two additional ECGs must be performed to confirm the safety finding. A monitoring or review process should be in place for clinically significant ECG findings throughout the study and especially before adminis tration of study 
treatment.  
Any identifier details must be redacted e.g. participant initials, date of birth. 
Clinically significant abnormalities must be recorded on the eCRF as either Medical 
history/Current medical condition or AEs as appropriate.  
8.4.3 Pregnancy  
Females of child -bearing potential are defined as all females physiologically capable of 
becoming pregnant. This includes female adolescent participants who are menarchal or who become menarchal during the study. 
Serum/urine pregnancy tests will be performed for all female adolescents of child -bearing 
potential according to the Assessment Schedule ( Table 8 -1). A positive urine pregnancy test 
should be confirmed with a serum pregnancy test. Additional pregnancy tests may be performed 
at the investigator’s discretion during the study and/or if requested by local requirements. 
Participants becoming pregnant must be discontinued from study drug. However, a participant 
may choose to remain in the study should she become pregnant, and be followed according to the protocol-defined study visits. 
All menarchal adolescents and their parent(s)/legal representative(s) should be informed about 
the potential risks of pregnancy and the need to prevent pregnancy during the study. 
It is important to be sensitive in introducing this issue, as understanding and comprehension of 
puberty, sexual activity, pregnancy and contraception is influenced by age as well as, factors such as precocity, socio(educational) economic and familial back ground. These discussions 
with the participant and her parent(s)/legal representative(s) are therefore best performed by investigators familiar with the adolescent participant and her family and should be guided by requirements of the local regulatory auth orities. These discussions should take into account the 
socio -economic, cultural factors and religious beliefs of the adolescent participant and her 
family. The investigator should also discuss the management of the pregnancy test results with the participant and her parent(s)/legal representative(s). The privacy of the participant should be considered in accordance with the local law and ethics.  
8.4.4 Other safety evaluations  
8.4.4.1 Pubertal development  
In addition to the assessment of height, weight and sexual hormones (see  Section  8.4.1), the 
following parameters will be monitored to evaluate pubertal development, at the time points detailed in the Schedule of Assessment ( Table 8 -1): 
Novartis  Confidential  Page 52 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
• Menarche (in females)  
• Tanner staging of sexual development (in males and females) 
Tanner staging will performed by a physician who (re-)familiarized him/herself with the Tanner 
stage assessment  (in case needed) . The results (stages 1 -5 for the respective characteristics) will 
be recorded on an appropriate eCRF. Once a participant reaches Tanner stage 5, evaluations 
can be discontinued. For females, the date of menarche will also be recorded on an appropriate eCRF . 
8.4.4.2 Neurological evaluation 
A full neurological evaluation will be performed as per the Schedule of Assessment  
(Table 8 -1). This should include assessment of motor function, sensory function, tone and 
reflexes and cerebellar function as detailed in  Section  16.5 (Appendix 5). 
Clinically significant abnormalities must be recorded on the eCRF as either Medical history/Current medical condition or AEs as appropriate.  
8.4.4.3 Injection site reactions 
Injection site reactions (ISRs) should be monitored at each visit from the randomization (Day 1) visit onwards ( Table 8 -1) and through additional contacts with the participant between visits 
as needed. ISRs including individual signs or symptoms at the injection site following study treatment administration should be recorded on an appropriate eCRF page. Every effort should be made to follow up with the participant until resolution of the ISR. 
8.4.4.4 Anaphylactic reactions 
Potential anaphylactic reactions should be assessed by Sampson criteria 
(see Section  16.6 (Appendix 6)). If Samson criteria are positive, confirmation by elevation of 
tryptase in blood plasma should be obtained within 30 minutes of the onset of anaphylaxis (or as soon as possible).  
8.4.4.5 Hyperglycemia- related events  
Laboratory results and newly added concomitant medications should be checked for potential hyperglycemia- related AEs.  
‘New onset of diabetes’ should be reported as AE on the eCRF in participants with no medical history of diabetes when: 
• HbA
1c becomes ≥6.5% and/or   
• Two consecutive values of FPG are ≥126 mg/dL (7.0 mmol/L)  
• If a new concomitant medication for control of plasma glucose is added, further information 
to assess for a diagnosis of new onset diabetes will need to be collected  
‘Worsening of glycemic control’ should be reported as AE on the eCRF  in participants with a 
medical history of disease (HbA 1c ≥6.5% at baseline) when:  
• HbA 1c increases from baseline >0.5%  
• New concomitant medication or increase in dose of current antidiabetic therapy is initiated to improve the control of plasma glucose level 
Novartis  Confidential  Page 53 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
8.4.5 Appropriateness of safety measurements 
The safety assessments selected for this trial are standard for this indication/adolescent 
population. They take into consideration safety data from adult studies and consultations with Health Authorities and are in accordance with guidelines (ICH Harmonis ed Guideline 
Addendum to ICH E11 ( ICH E11  (R1) 2017)).  
8.5 Additional assessments 
  
  
 
  
 
 
8.
5.2 Biomarkers 
No exploratory biomarkers will be evaluated in this study. The assessment of lipids/lipoproteins 
and PCSK9 is discussed in Section  8.3. 
  
    
 
 
 
  
 
  
 

Novartis  Confidential  Page 54 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
9 Study discontinuation and completion 
9.1 Discontinuation and completion  
9.1.1 Study treatment discontinuation and study discontinuation 
Discontinuation of study treatment for a participant occurs when study treatment is stopped 
earlier than the protocol planned duration, and can be initiated by either the participant’s parent(s)/legal representative(s) / participant (if applicable) or the investigator. 
The investigator must discontinue study treatment for a given participant if, he/she believes that 
continuation would negatively impact the participant's well -being. After study treatment 
discontinuation, participants should remain in the study and complete other study visit procedures as per the Assessment Schedule, unless consent is withdrawn ( Section  9.1.2), 
preferably in writing.  
Study treatment must be discontinued under the following circumstances: 
• Participant’s parent(s)/legal representative(s) / participant (if applicable) decision  
• Pregnancy 
• Use of prohibited treatment as per details in the prohibited treatment section (Table 6 -2) 
• Following emergency unblinding 
• Any situation in which study participation might result in a safety risk to the participant 
• Severe and persistent (>14 days despite appropriate treatment) reactions at the injection site 
and any confirmed anaphylactic reactions 
• Unexplained increases in transaminases (ALT or AST) or total bilirubin as follows:  
• ALT or AST >5x ULN  
• ALT or AST >3x ULN for more than 2 weeks 
• ALT or AST >3x ULN and (total bilirubin >2x ULN or INR >1.5) 
• ALT or AST >3x ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
• The investigator should evaluate to see if other causes for the laboratory abnormalities are immediately apparent, such as obstructive gall bladder or bile duct disease, viral or alcoholic hepatitis, malignancy involving the liver, congestive hepatopathy, other hepatotoxins or heritable disorders. 
• Unexplained C(P)K values >5x ULN confirmed by repeat test when the C(P)K elevation is associated with muscle pain, muscle tenderness and/or muscle weakness, or new onset renal dysfunction 
• Any other laboratory abnormalities that, in the judgment of the investigator, prevents the participant from continuing study treatment  
In addition, adolescent females who gain child -bearing potential during the study and are 
unwilling to comply with the requirements for contraception as outlined in Section  5.2 will be 
excluded from receiving further study drug. 
Novartis  Confidential  Page 55 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
If discontinuation of study treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the participant’s premature discontinuation of study treatment and record this information.  
Study treatment may be restarted at the discretion of the investigator, if the reason for discontinuation has resolved. Every effort should be made to restart study treatment, if deemed appropriate by the investigator. Study treatment is not allowed to be re -started following 
initiation of prohibited medication that requires study drug discontinuation ( Table 6 -2). 
Participants who discontinue study treatment or for whom the participant’s parent(s)/legal representative(s) / participant (if applicable) decide that they do not to wish the participant to participate in the study further, should NOT be considered withdrawn from the study UNLESS informed consent was withdrawn (see Withdrawal of informed consent, Section  9.1.2). Where 
possible, they should return for the assessments indicated in the Assessment Schedule. If they fail to return for these assessments for unknown reasons, every effort (e.g. telephone, e -
mail, letter) should be made to contact the participant’s parent(s)/legal representative(s) / participant / pre -designated contact  as specified in the lost to follow -up section. This contact 
should preferably be done according to the study visit schedule. 
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain 
regular telephone contact with the participant, the participant’s parent(s)/legal representative(s) or with another pre -designated person. This telephone contact should preferably be done 
according to the study visit schedule.  
After study treatment discontinuation, at a minimum, in abbreviated visits, the following data should be collected at clinic visits and/or via telephone/email contact: 
• New / concomitant treatments  
• AEs/SAEs  
Where possible, all clinic visit assessments should be performed according to Table 8 -1. 
The investigator must also contact the IRT to register the participant’s discontinuation from 
study treatment. 
If discontinuation occurs because the treatment code has been broken, please refer to the 
Emergency breaking of treatment code section ( Section  6.6.3).  
9.1.2 Withdrawal of informed consent  
Participants’ parent(s)/legal representative(s) / participants (if applicable) may voluntarily withdraw consent for the participant to participate in the study for any reason at any time. Withdrawal of consent occurs only when a participant’s parent(s)/leg al representative(s) / 
participant (if applicable):  
• Does not want the participant to participate in the study anymore, 
and 
• Does not want any further visits or assessments  
and • Does not want any further study related contacts 
Novartis  Confidential  Page 56 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the decision to withdraw consent and record this 
information. 
Where consent to the use of personal and coded data is not required, participants’ parent(s)/legal 
representative(s) / participants (if applicable) therefore cannot withdraw consent. They still retain the right to object to the further use of personal data. 
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.  
Further attempts to contact the participant are not allowed unless safety findings require communicating or follow -up. 
All efforts should be made to complete the assessments prior to study discontinuation. A final evaluation at the time of the participant’s study discontinuation should be made as detailed in the Assessment Table ( Table 8 -1). 
Novartis will continue to retain and use all research results (data) that have already been collected for the study evaluation.  
Any adolescent’s (for whom the parent(s)/legal representative(s) provided informed consent) request to be withdrawn from the study should be respected and discussed in detail with the participant’s parent(s)/legal representative(s) and the local investigator before acting upon the request.   
9.1.3 Lost to follow -up 
For participants whose status is unclear because they fail to appear for study visits without stating an intention to discontinue or withdraw, the investigator must show "due diligence" by documenting in the source documents steps taken to contact the part icipant / participant’s 
parent(s)/legal representative(s), e.g. dates of telephone calls, registered letters, etc. A participant should not be considered as lost to follow -up until the end of each study part while 
due diligence has been completed. 
9.1.4 Early study termination by the sponsor  
The study can be terminated by Novartis at any time. 
Reasons for early termination:  
• Unexpected, significant, or unacceptable safety risk to participants enrolled in the study 
• Decision based on recommendations from applicable board(s) after review of safety and 
efficacy data 
• Discontinuation of study drug development 
In taking the decision to terminate, Novartis will always consider participant welfare and safety. Should early termination be necessary, participants must be seen as soon as possible and treated as a prematurely withdrawn participant. The investigator may  be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the protection of the participant’s interests. The investigator or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.  
Novartis  Confidential  Page 57 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
9.2 Study completion and post -study treatment  
Study completion is defined as when the last participant finishes their Study Completion visit 
and any repeat assessments associated with this visit have been documented and followed -up 
appropriately by the Investigator or, in the event of an early study termination decision, the date of that decision. 
All treated participants should have a safety follow -up call conducted 30 days after their last 
study visit or 90 days after the last administration of study drug, whatever is longer. The 
information collected is kept as source documentation. All SAEs reported during this time period must be reported as described in Section  10.1.3. Documentation of attempts to contact 
the participant should be recorded in the source documentation. 
The decision whether there will be a post -study treatment with inclisiran in pediatric patients 
with HeFH will not occur before an adequate benefit- risk assessment. Should the assessment 
be positive and a post -study treatment be initiated, participants who  complete the trial may have 
the opportunity to join such post- study treatment.  
10 Safety monitoring and reporting  
10.1 Definition of adverse events and reporting requirements  
10.1.1 Adverse events 
An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign 
[including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after written informed consent was provided for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has the responsibility for managing the safety of individual participant and identifying AEs. 
Novartis qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.  
The occurrence of AEs must be sought by non- directive questioning of the participant at each 
visit during the study. Adverse events also may be detected when they are volunteered by the participant during or between visits or through physical examination findings, laboratory test findings, or other assessments. 
Adverse events must be recorded in the AE eCRF under the signs, symptoms, or diagnosis 
associated with them, accompanied by the following information (as far as possible) (if the event is serious refer to Section  10.1.2):  
1. The severity grade:  
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
Novartis  Confidential  Page 58 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
2. Its relationship to the study treatment. If the event is due to lack of efficacy or progression 
of underlying illness (i.e. progression of the study indication) the assessment of causality will usually be ‘Not suspected.’ The rationale for this guidance is  that the symptoms of a 
lack of efficacy or progression of underlying illness are not caused by the trial drug, they happen in spite of its administration and/or both lack of efficacy and progression of underlying disease can only be evaluated meaningfully by an analysis of cohorts, not on a 
single participant  
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not resolved must be reported  
4. Whether it constitutes a SAE (see Section  10.1.2 for definition of SAE) and which 
seriousness criteria have been met  
5. Action taken regarding with study treatment 
All AEs must be treated appropriately. Treatment may include one or more of the following: 
• Dose not changed 
• Drug interrupted/withdrawn  
6. Its outcome (i.e. not recovered/not resolved, recovered/resolved, recovering/resolving, recovered/resolved with sequelae, fatal or unknown) 
Conditions that were already present at the time of informed consent should be recorded in the medical history of the participant.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Once an AE is detected, it must be followed until its resolution or until it is judged to be 
permanent (e.g. continuing at the end of the study), and assessment must be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome. 
Information about ADRs for the investigational drug can be found in the IB. Abnormal laboratory values or test results constitute AEs only if they fulfill at least one of the 
following criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically significant  
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non- typical in participants 
with the underlying disease. Alert ranges for laboratory abnormalities are included in Section  16.2  (Appendix 2). 
10.1.2 Serious adverse events 
An SAE is defined as any AE [appearance of (or worsening of any pre -existing)] undesirable 
sign(s), symptom(s) or medical conditions(s)) which meets any one of the following criteria:  
Novartis  Confidential  Page 59 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (please refer to the ICH-E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospitalization or prolongation of existing hospitalization, unless hospitalization is for:  
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition (HeFH) 
• elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
• social reasons and respite care in the absence of any deterioration in the participant’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospital admission 
• is medically significant, e.g. defined as an event that jeopardizes the participant or may 
require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospitalization but might jeopardize the participant or might 
require intervention to prevent one of the other outcomes listed above. Such events should be considered as “medically significant”. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or development of dependency or abuse (please refer to the ICH -
E2D Guidelines). 
All new malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.  
Any suspected transmission via a medicinal product of an infectious agent is also considered a serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered SAEs irrespective if a clinical event has occurred (Table 10-1).  
10.1.3 SAE reporting  
To ensure participant safety, every SAE, regardless of causality, occurring after informed consent was provided and until 30 days after the last study visit (or  90 days after the last 
administration of study drug, whatever is longer) must be reported to Novartis Safety immediately, without undue delay, but under no circumstances later than within 24 hours of obtaining knowledge of the events (Note: If more stringent, local regulations regarding reporting timelines prevail). Detailed instructions regarding t he submission process and 
requirements are to be found in the investigator folder provided to each site. 
Novartis  Confidential  Page 60 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
SAE reporting time frames are as follows:  
1. Screen failures: SAEs occurring after informed consent was provided until the time the 
participant is deemed a Screen Failure must be reported to Novartis.  
2. Randomized participants: SAEs collected between time informed consent was provided 
until 30 days after the last study visit (or  90 days after the last administration of study drug, 
whatever is longer) must be reported to Novartis. 
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
immediately, without undue delay, but under no circumstances later than within 24 hours of the 
investigator receiving the follow -up information (Note: If more stringent, local regulations 
regarding reporting timelines prevail). An SAE occurring at a different time interval or otherwise considered completely unrelated to a previously reported one must be reported separately as a new event.  
If the SAE is not previously documented in the IB or Package Insert (new occurrence) and is suspected to be related to the study treatment, this event is considered a Suspected Unexpected Serious Adverse Reaction (SUSAR). A Chief Medical Office and Patient  Safety (CMO & PS) 
Department associate may urgently require further information from the investigator for health authority reporting. Novartis may need to issue an Investigator Notification to inform all investigators involved in any study with the same s tudy treatment that this SAE has been 
reported. 
SUSARs will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with European Union (EU) Guidance 2011/C 172/01 or as per national regulatory requirements in participating countries.  
Any SAE experienced after the 30 days period following the last study visit (or  90 days after 
the last administration of study drug, whatever is longer) should only be reported to Novartis Safety if the investigator suspects a causal relationship to study treatment.  
10.1.4 Pregnancy reporting  
Pregnancies  
If a female trial participant becomes pregnant, the study treatment should be stopped, and the participant’s parent(s)/legal representative(s) / participant (if applicable) must be asked to read and sign a pregnancy consent form to allow the Study Doctor ask about her pregnancy. To ensure participant safety, each pregnancy occurring after signing the informed consent must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be followed up until one year after the baby was due to be born  to determine outcome, including 
spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications.  
Pregnancy should be recorded and reported by the investigator to the Novartis CMO&PS. Pregnancy follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the investigational treatment of any pregnancy outcome. Any SAE experienced during pregnancy must be reported.  
Novartis  Confidential  Page 61 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
10.1.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or consumer (European Medicines Agency (EMA) definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the protocol. 
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by harmful physical or psychological effects. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
an appropriate dosing eCRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse 
Treatment error type Document in Dosing 
eCRF (Yes/No)  Document in AE eCRF  Complete SAE form 
Unintentional study 
treatment error  Yes Only if associated with an 
AE Only if associated with an 
SAE 
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE  
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.  
10.2 Additional Safety Monitoring  
10.2.1 Liver safety monitoring 
To ensure participant safety and enhance reliability in determining the hepatotoxic potential of an investigational drug, a standardized process for identification, monitoring and evaluation of liver events has to be followed. 
Please refer to Table 16 -3 (Section 16.3 (Appendix 3)) for complete definitions of liver 
laboratory triggers.  
Once a participant is exposed to study treatment, every liver event defined in Table 16-3 should 
be followed up by the investigator or designated personnel at the trial site, as summarized below. Additional details on actions required in case of liver events are outlined in Table 16-4  
and Table 16-5 ( Section 16.3 (Appendix 3)). Requirements for follow -up of potential DILI 
cases is provided in Section  6.5.2.1. 
• Repeat liver chemistry tests (i.e. ALT, AST, total bilirubin, direct and indirect bilirubin, PT/INR, ALP , GGT , GLDH, albumin and C(P)K ) to confirm elevation.  
• These liver chemistry repeats will be performed using the central laboratory. If results will not be available from the central laboratory, then the repeats can also be performed at a local laboratory to monitor the safety of the participant. If a liver ev ent is subsequently reported, 
Novartis  Confidential  Page 62 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
any local liver chemistry tests previously conducted that are associated with this event 
should have results recorded on an appropriate eCRF. 
• If the initial elevation is confirmed, close observation of the participant will be initiated, including consideration of treatment interruption if deemed appropriate.  
• Discontinuation of the investigational drug (refer to the Discontinuation of study treatment section), if appropriate 
• Hospitalization of the participant, if appropriate  
• Causality assessment of the liver event  
• Thorough follow-up of the liver event should include  
• These investigations can include based on investigator’s discretion: serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease 
All follow -up information and procedures performed must be recorded as appropriate in the 
eCRF.  
10.2.2 Renal safety monitoring 
To ensure participant safety and enhance reliability in determining the nephrotoxicity potential of an investigational drug, a standardized process for identification, monitoring and evaluation of renal events has to be followed. 
Every renal laboratory trigger or renal event as defined in Table 16 -6 (Section 16.4 (Appendix 
4)) should be followed up by the investigator or designated personnel at the trial site as 
summarized in Table 16-7 ( Section 16.4 (Appendix 4)). 
10.2.3 Other safety monitoring 
The frequency and severity of the AEs listed below will be monitored during the study. They will be reviewed by the DMC at regular intervals.  
• ISRs (see also Section  8.4.4.3), hypersensitivity reactions and immune- mediated reactions  
• Hepatobiliary AEs and liver -related biochemical abnormalities (see also Section  6.5.2.1  and 
Section  10.2.1) 
• Musculoskeletal AEs and muscle- related biochemical abnormalities (e.g. C(P)K) 
• Neurological or psychiatric AEs  
• New onset of diabetes or worsening of glycemic control in diabetics (see also Section  8.4.4.5) 
10.2.4 Data Monitoring Committee  
This study will include a DMC, which will function independently of all other individuals associated with the conduct of this clinical trial, including the site investigators participating in the study. The DMC will assess at defined intervals the progress of the clinical trial, review safety data, and recommend to the sponsor whether to continue, modify or terminate the trial.  
Novartis  Confidential  Page 63 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
It is anticipated that the DMC will review safety data 90 days after the first 75 participants 
received the first injection of study drug and every 3 months thereafter until EOS, unless requested otherwise by the DMC.  
Specific details regarding composition, responsibilities, data monitoring and meeting frequency, and documentation of DMC reports, minutes, and recommendations will be described in a separate DMC charter that is established between the sponsor and the DMC.  
10.2.5 Steering Committee  
The Steering Committee (SC) will be established comprising representatives associated with the trial, but not being members of the DMC. Novartis representatives from the Global Clinical Team can be present at the SC meetings.  
The SC will ensure transparent management of the study according to the protocol through recommending and approving modifications as circumstances require. The SC will review protocol amendments as appropriate. Together with the clinical team, the SC will also develop recommendations for publications of study results including authorship rules. The details of the role of the SC will be defined in the SC charter.  
11 Data Collection and Database management  
11.1 Data collection  
Designated investigator staff will enter the data required by the protocol into eCRFs. The eCRFs have been built using fully validated secure web- enabled software that conforms to 21 Code of 
Federal Regulation (CFR) Part 11 requirements, Investigator site staff will not be given access to the Electronic Data Capture (EDC) system until they have been trained. Automatic validation programs check for data discrepancies in the eCRFs, allow modification and/or verification of the entered data by the investigator  staff.  
The investigator/designee is responsible for assuring that the data entered into the eCRF is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate  
After final database lock, the investigator will receive copies of the participant data for archiving at the investigational site.  
All data should be recorded, handled and stored in a way that allows its accurate reporting, interpretation, and verification.  
11.2 Database management and quality control  
Novartis personnel (or designated Contract Research Organization (CRO)) will review the data entered by investigational staff for completeness and accuracy. Electronic data queries stating the nature of the problem and requesting clarification will be crea ted for discrepancies and 
missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data.  
Novartis  Confidential  Page 64 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Medical history/current medical con ditions and 
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Dates of screenings, randomizations, screen failures and study completion, as well as 
randomization codes and data about all study treatment (s) dispensed and all dosage changes will be tracked using an IRT. The system will be supplied by a vendor, who wil l also manage 
the database. The data will be sent electronically to Novartis (or a designated CRO) at specific timelines.  
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of Novartis.  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be unblinded and made available for data analysis. Any changes to the database after that time can only be made after 
written agreement by Novartis Development management.  
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis representative will review the protocol and data capture requirements (i.e. eCRFs) with the investigators and their staff. During the study, Novartis employs se veral methods of ensuring 
protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of participant records, the accuracy of data capture / data entry, the adherence to the protocol and to GCP, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits.  
The investigator must maintain source documents for each participant in the study, consisting of case and visit notes (hospital or clinic medical records) containing demographic and medical information, laboratory data, ECGs, and the results of any other t ests or assessments. All 
information on eCRFs must be traceable to these source documents in the participant’s file. The investigator must also keep the original signed ICF and the original signed assent form, if 
applicable (a signed copy is given to the p articipant’s parent(s)/legal representative(s)/ 
participant (if applicable)).  
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. Novartis monitoring standards require full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the eCRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.  
Novartis  Confidential  Page 65 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
12 Data analysis and statistical methods 
Details of the statistical analysis and data reporting will be summarized in the Statistical 
Analysis Plan (SAP) document finalized before data lock. Any data analysis carried out independently by the investigator should be submitted to Novartis before publication or presentation.  
Efficacy and safety analyses of Part 1 data will be performed after all participants have completed the Day 360 visit or discontinued prior to the Day 360 visit. All available data from the clinical database will be included in the analysis. Formal testing  of the primary and key 
secondary endpoints with full alpha level will be performed for the Part 1 data. This analysis will be unblinded and reviewed by the CTT. 
12.1 Analysis sets  
The Full Analysis Set (FAS) comprises of all randomized participants with the exception of those mis -randomized participants who did not receive study drug. Mis -randomized participants 
are defined as not qualified for randomization and are inadvertently ra ndomized into the study. 
According to the intent to treat principle, participants will be analyzed according to the treatment they have been assigned to during the randomization procedure. The FAS will be used in analyses for the primary, secondary, . 
The Safety Set includes all participants who received at least one dose of study treatment. Participants will be analyzed according to the study treatment received. This will be the primary population for the safety analyses. 
12.2 Participant demographics and other baseline characteristics  
Demographic and other baseline data including medical history will be summarized descriptively by treatment group for the FAS.  
Categorical data will be presented as frequencies and percentages by treatment group. For continuous data, non- missing observations, mean, standard deviation, median, minimum, and 
maximum will be presented. For continuous data, the 1st and 3rd quartile will also be presented by treatment group. 
Relevant medical histories and current medical conditions at baseline will be summarized 
separately by system organ class and preferred term, by treatment group. Histories of statin intolerance and underlying genetic mutation will be summarized by treatment group. 
12.3 Treatments  
The Safety set will be used for the analyses below.  
The number of participants dosed at each dosing visit, number of study doses administered,  duration of exposure in days, and dose administered will be summarized by 
treatment group. The number of study doses administered will be summarized by study part an d 
overall (Parts 1 and 2 combined). 
Lipid -modifying therapy use and LDL -apheresis at screening and the baseline/Randomization 
visit (Day 1) will be summarized by treatment group. New or changed lipid- modifying therapy 
and LDL- apheresis after baseline will be summarized by treatment group and  part.  

Novartis  Confidential  Page 66 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Other concomitant medications and significant non -drug therapies prior to and after the start of 
the study treatment will be summarized according to the Anatomical Therapeutic Chemical 
(ATC) classification system, by treatment group and part.  
12.4 Analysis of the primary endpoint(s)/estimand(s)  
12.4.1 Definition of primary endpoint and estimand  
The primary estimand is defined in Section  2.1. The corresponding endpoint, i.e. primary 
analysis variable, is the percentage change in LDL -C from the pre -dose baseline measurement 
to the Day 330 visit. 
12.4.2 Statistical model, hypothesis, and method of analysis 
The primary objective of this study is to demonstrate superiority of inclisiran compared to 
placebo in reducing the percentage change from baseline in LDL -C to Day 330 in adolescents 
with HeFH and elevated LDL -C. The statistical hypotheses that will be tested are as follows:  
• H0: The difference (inclisiran minus placebo) between participants treated with inclisiran and placebo in the least squares mean percentage change from baseline to the Day 330 visit in LDL -C= 0  
• Ha: The difference (inclisiran minus placebo) between participants treated with inclisiran and placebo in the least squares mean percentage change from baseline to the Day 330 visit in LDL -C < 0  
The primary objective will be achieved if the null hypothesis is rejected using the  one-sided 
significance level of 0.025 to test superiority of inclisiran treatment.  
The primary analysis will use an analysis of covariance (ANCOVA) model. The model will include the fixed effects of treatment group and baseline age group (≥12 -<15 or  ≥15-<18 years 
of age) with baseline LDL -C as a covariate. Multiple imputation will be used to impute missing 
data using a washout model. A total of 100 imputed datasets will be created. The ANCOVA model will be fit to each imputed dataset, and results will be combined using Rubin's combination rules. The difference in least squares means between treatment groups and corresponding 2- sided 95% confidence intervals will be calculated. The FAS will be used for 
this analysis. Full details on the model and imputation will be provided in the SAP. 
The washout model will be used to explore the assumption that missing Day 330 visit data are 
missing not at random in participants in the inclisiran group who discontinue the study treatment early before the Day 330 visit and cannot be followed for schedul ed LDL -C assessments. Early 
terminating participants in the placebo group will have missing data imputed based on the missing at random assumption. Full details will be provided in the SAP. 
12.4.3 Handling of remaining intercurrent events of primary estimand 
No remaining intercurrent events are expected.  
Novartis  Confidential  Page 67 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
12.4.4 Handling of missing values not related to intercurrent event  
Other missing data are expected to be intermittent missing data and will be assumed to be 
missing at random. Imputation details for data missing at random in the washout model will be provided in the SAP. 
12.4.5 Sensitivity analyses for primary endpoint/estimand 
The following sensitivity analyses will be performed for the primary estimand, to assess the 
robustness of the estimation in the presence of deviations from the assumptions specified in the primary analysis: 
• Linear mixed -effect model for repeated measures (MMRM) analysis without multiple 
imputation  
• MMRM analysis using a control-based pattern mixture model 
• ANCOVA using the washout model including the following fixed effects: concomitant 
lipid-modifying therapies, baseline age group, country, and a treatment -by-country 
interaction  
Analyses using the MMRM will include fixed effects for treatment, visits, interaction between treatment and visits, baseline LDL -C, and baseline age group. The Restricted Maximum 
Likelihood (REML) estimation approach will be used with covariance structure set as "Unstructured".  
The control -based pattern mixture model will be used to further explore the possibility of 
missing data being missing not at random. This approach will utilize placebo data for monotone 
missing inclisiran treatment data.   
Full details for sensitivity analyses will be provided in the SAP.  
12.4.6 Supplementary analysis 
Supplementary analyses of LDL -C percent change from baseline to Day 330 will be performed 
in select subgroups. The MMRM will be used to evaluate the difference between inclisiran and placebo groups in each subgroup. Subgroups will include, but not be limited to, sex, age group, 
and baseline statin treatment. Additional subgroups will be specified in the SAP along with 
further details of supplementary analyses.  
12.4.7 Supportive analyses  
No supportive analyses are planned. 
12.5 Analysis of secondary endpoints/estimands  
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s)  
The following are key secondary efficacy endpoints: 
1. Time -adjusted percent  change in LDL -C from baseline after Day 90 and up to Day 330 
(Year 1)  
2. Absolute change in LDL- C from baseline to Day 330 (Year 1) 
3. Percent change in Apo B from baseline to Day 330 (Year 1) 
Novartis  Confidential  Page 68 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
4. Percent change in  Lp(a) from baseline to  Day 330 (Year 1) 
5. Percent change in  non- HDL -C from baseline to  Day 330 (Year 1) 
6. Percent change in  total cholesterol from baseline to  Day 330 (Year 1) 
A hierarchical testing strategy will be applied to control the family -wise type I error rate at the 
significance level of 0.025 (one -sided test) to assess superiority of inclisiran over placebo. 
Hypotheses associated with the key secondary endpoints will be tested in the order listed above. 
The key secondary endpoints will be analyzed using ANCOVA  with imputation performed 
using the washout model as discussed in Section  12.4.2. Details, including possible sensitivity 
analyses performed using the MMRM, will be provided in the SAP.  
Other secondary efficacy endpoints include the percent change and absolute change from 
baseline throughout the time course up to Day 720 (Year 2) in the following: 
• LDL -C 
• Apo B 
• Lp(a)  
• non-HDL -C 
• total cholesterol  
• triglycerides  
• HDL -C 
• VLDL -C 
• Apo A1  
• PCSK9  
Descriptive summaries by treatment group will be presented.  
12.5.2 Safety endpoints 
For all safety analyses, the safety set will be used. All tables will be presented by treatment 
group. 
Safety summaries (tables, figures) include only treatment emergent events (events started after 
the first dose of study medication or events present prior to start of double -blind treatment but 
increased in severity based on preferred term) with the exception of baseline data which will also be summarized where appropriate (e.g. change from baseline summaries). In addition, a separate summary for deaths including on treatment and post treatment deaths will be provided. In particular, summary tables for adve rse events (AEs) will summarize only treatment emergent 
AEs.  
Adverse events 
The number (and percentage) of participants with treatment emergent adverse events in Part 1 
and Part 2 will be summarized in the following ways:  
• by treatment, primary system organ class and preferred term alphabetically.  
• by treatment, primary system organ class, preferred term alphabetically  and maximum 
severity.  
Novartis  Confidential  Page 69 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
• by treatment, primary system organ class and preferred term alphabetically for  treatment 
emergent  AEs leading to study drug discontinuation. 
• by treatment, primary system organ class and preferred term alphabetically for  treatment 
emergent  AEs related to study drug. 
The number  (and percentage) of  participants with treatment emergent serious adverse events in 
Part 1 and Part 2  will be summarized in the following ways: 
• by treatment, primary system organ class and preferred term  alphabetically.  
• by treatment, primary system organ class and preferred term alphabetically for  treatment 
emergent  serious AEs related to study drug. 
A separate summary  will be provided for adverse events leading to death. 
The number (and proportion) of participants with adverse events of special interest will be 
summarized by treatment. Categories of AEs used in this analysis will be specified in the SAP.  
A participant with multiple adverse events within a primary system organ class is only counted once towards the total of the primary system organ class.  
Vital signs  
All vital signs data will be listed by treatment group, participant, and visit/time and if ranges are available, abnormalities (and relevant orthostatic changes) will be flagged. Summary statistics will be provided by treatment and visit/time.  
Baseline and change from baseline in height, weight, and BMI will be assessed using age- and sex-adjusted z-scores and summarized by treatment group. 
Clinical laboratory evaluations 
Summary statistics will be provided by treatment group and visit. Shift tables using the low, 
normal, or high classification will be used to compare baseline to the worst on -treatment value 
by treatment group for Part 1 and overall. The number (and percentage) of participants meeting clinically significant criteria will be provided by treatment group for Part 1 an d overall. 
Immunogenicity  
ADA evaluations, including treatment emergent ADA findings, will be summarized by treatment group, participant, and visit. Additional analyses may be performed to describe the relationship between  ADA and other study findings and will be detailed in the SA P. 
Other safety evaluations  
Baseline Tanner stage will be summarized by treatment group. Shift from baseline in Tanner stage and menarche in female participants without menarche at baseline will be summarized by treatment group.   
12.5.3 Biomarkers 
Analyses of PCSK9 and lipids/lipoproteins are discussed in Section  12.5.1. No additional 
biomarkers will be evaluated in this study.  
Novartis  Confidential  Page 70 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
  
  
 
    
 
   
 
  
 
•
  
•  
•  
•  
•  
  
  
   
12.7 Interim analyses  
Interim analyses are planned for the monitoring of participants' safety and will be performed following the schedule specified in Section  10.2.4. Interim safety analyses before the 
unblinding for the analysis of Part 1 of the study will be performed by an independent statistician/programmer who will not be involved in the trial conduct. The interim results will be reviewed by the independent DMC. 
   

Novartis  Confidential  Page 71 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
12.8 Sample size calculation  
12.8.1 Primary endpoint(s)  
The sample size was calculated based on detecting a reduction of at least n the inclisiran 
group compared to the placebo group in percent change of LDL -C from baseline. The percent 
difference is assumed to have a standard deviation of  in the control group and  in the inclisiran group. These assumptions are based on observed results from adult inclisiran studies.  
The sample size of at least  total participants will provide more than  power to detect a 
 reduction with the
Further more , in the adult HeFH inclisiran study (ORION -9), a SD of  in the control group 
and  in the inclisiran group was observed . With a more conservative assumption of a SD 
of  in the control group and in the inclisiran group, the sample size of at least total 
participants will still provide more than power to detect a reduction with a one -sided 
significance level of 0.025. 
The revised sample size requires a minimum of participants; however, the actual anticipated 
en
rollment is approximately participants.
13 Ethical considerations and administrative procedures 
13.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized Tripartite Guidelines for GCP, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethic al principles laid 
down in the Declaration of Helsinki.  
13.2 Responsibilities of the investigator and IRB/IEC  
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from the IRB/IEC for the trial protocol, written ICF(s), written assent form (if applicable), consent/assent form updates, participant recruitment procedures (e. g., advertisements) and any 
other written information to be provided to participants. Prior to study start, the investigator is required to sign a protocol signature page confirming his/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this 

Novartis  Confidential  Page 72 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Quality Assurance representatives, designated agents of Novartis, IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site  is requested by a regulatory 
authority, the investigator must inform Novartis immediately that this request has been made.  
13.3 Publication of study protocol and results  
The protocol will be registered in a publicly accessible database such as clinicaltrials.gov and as required in European Union Drug Regulating Authorities Clinical Trials (EudraCT). In addition, after study completion (defined as last patient last visit) a nd finalization of the study 
report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the Novartis clinical trial results website and all required Health Authority we bsites (e.g. Clinicaltrials.gov, EudraCT etc.). 
For details on the Novartis publication policy including authorship criteria, please refer to the Novartis publication policy training materials that were provided to you at the trial investigator meetings.  
13.4 Quality Control and Quality Assurance  
Novartis maintains a robust Quality Management System that includes all activities involved in quality assurance and quality control, to ensure compliance with written Standard Operating Procedures (SOPs) as well as applicable global/local GCP regulations and ICH Guidelines. 
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols and internal SOPs, and are performed according to written Novartis processes. 
14 Protocol adherence 
This protocol defines the study objectives, the study procedures and the data to be collected on study participants. Additional assessments required to ensure safety of participants should be administered as deemed necessary on a case by case basis. Under no circumstances including incidental collection is an investigator allowed to collect additional data or conduct any additional procedures for any purpose involving any investigational drugs under the protocol, other than the purpose of the study. If despite this interdiction prohibition, data, information, observation would be incidentally collected, the investigator shall immediately disclose it to Novartis and not use it for any purpose other than the study, except for the appropriate monitoring on study participants. 
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study this must be considered a protocol amendment, and unless such an amendment is agreed upon by Novartis and approved by the IRB/IEC and health authorities, where required, it cannot be implemented. 
Novartis  Confidential  Page 73 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
14.1 Protocol amendments  
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by protocol amendment and the reviewing IRB/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any participant included in this study, even if this action represents a deviation from the protocol. In such cases, Novartis should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
Novartis  Confidential  Page 74 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
15 References 
References are available upon request  
Baigent C, Keech A, Kearney PM, et al (2005) Efficacy and safety of cholesterol -lowering 
treatment: prospective meta -analysis of data from 90,056 participants in 14 randomised trials 
of statins. Lancet; 366:1267-78. 
Barkas F, Liberopoulos EN, Kostapanos MS, et al (2015) Lipid target achievement among 
patients with very high and high cardiovascular risk in a lipid clinic. Angiology; 66(4):346-53. 
Casula M, Tragni E, Catapano AL (2012) Adherence to lipid- lowering treatment: the patient 
perspective. Patient Prefer Adherence; 6:805 -14. 
Clinical Trials Facilitation and Coordination Group CTFG  (2020) . Recommendations related 
to contraception and pregnancy testing in clinical trials. Version 1.1. (Internet) Available 
from: <httpswww.hma.eu/fileadmin/dateien/Human_Medicines/01 About_HMA/Working_Groups/CTFG/2020_09_HMA_CTFG_Contraception_guidance_Version_1.1_updated.pdf> (Accessed 28- Oct-2022). 
Daniels SR, Pratt CA, Hayman LL (2011) Reduction of Risk for Cardiovascular Disease in Children and Adolescents. Circulation; 124(15):1673-86. 
Daniels S, Caprio S, Chaudhari U, et al  (2020) PCSK9 inhibition with alirocumab in pediatric 
patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. J Clin 
Lipidol; 14(3):322-30. 
Davidson MH, Maki KC, Pearson TA, et al (2005) Results of the National Cholesterol 
Education (NCEP) Program Evaluation ProjecT Utilizing Novel E -Technology (NEPTUNE) 
II survey and implications for treatment under the recent NCEP Writing Group recommendatio ns. Am J Cardiol; 96:556-63. 
European Atherosclerosis Society (2015) Commentary on Paediatric FH: Landmark Position Paper on Paediatric Familial Hypercholesterolaemia from the EAS Consensus Panel. (Internet) Available from: eas -society.org/page/ped_fh_comment (Accessed 27 Jan 2020). 
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute (2011) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics; 128 Supp 5:S213-S256. 
Ference BA, Ginsberg HN, Graham I, et al (2017) Low-density lipoproteins cause 
atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J; 38(32):2459-72. 
Fitzgerald K, White S, Borodovsky A, et al (2017) A Highly Durable RNAi Therapeutic 
Inhibitor of PCSK9. N Engl J Med; 376(1):41-51. 
Gidding SS, Champagne MA, de Ferranti SD, et al (2015) The Agenda for Familial 
Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation; 132(22):2167-92. 
Novartis  Confidential  Page 75 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Giugliano RP, Pedersen TR, Park J- G, et al (2017) Clinical efficacy and safety of achieving 
very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a 
prespecified secondary analysis of the FOURIER trial. Lancet; 390:1962–71. 
Go AS, Mozaffarian D, Roger VL, et al (2014) Heart disease and stroke statistics -2014 
update: a report from the American Heart Association. Circulation; 129:e28 -e292. 
Grundy SM, Cleeman JI, Bairey Merz CN, et al (2004) Implications of recent clinical trials 
for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation; 110:227-39.  
Howie SRC (2011) Blood sample volumes in child health research: review of safe limits. Bull 
World Health Organ; 89:46-53. 
ICH Harmonized Guideline Addendum to ICH E 11 (2017) Clinical investigation of medicinal 
products in the pediatric population E11 (R1). (Internet) Available from: 
database.ich.org/sites/default/files/E11_R1_Addendum.pdf (Accessed 10 Jun 2020). 
Jameson K, Zhang Q, Zhao C, et al (2014) Total and low- density lipoprotein cholesterol in 
high- risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a 
primary -care database. Curr Med Res Opin; 30(4):655-65. 
Jones PH, Nair R, Thakker KM (2012) Prevalence of dyslipidemia and lipid goal attainment 
in statin treated participants from 3 data sources: a retrospective analysis. J Am Heart Assoc; 1(6):e001800. 
Khvorova A (2017) Oligonucleotide Therapeutics - A New Class of Cholesterol -Lowering 
Drugs. N Engl J Med; 376(1):4-7. 
Lakoski SG, Lagace TA, Cohen JC, et al (2009) Genetic and metabolic determinants of 
plasma PCSK9 levels. J Clin Endocrinol Metab; 94:2537-43. 
Momper JD, Mulugeta Y, Green DJ, et al (2013) Adolescent dosing and labeling since the 
Food and Drug Administration Amendments Act of 2007. JAMA Pediatr; 167(10):926-32. 
Mousavi SA, Berge KE, and Leren TP (2009) The unique role of proprotein convertase 
subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med; 266(6):507- 19. 
Najam O, Ray KK (2015) Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. Cardiol Ther; 4(1):25-38. 
Newman CB, Preiss D, Tobert JA, et al (2019) Statin Safety and Associated Adverse Events: 
A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol; 39:e38–e81. 
Raal FJ, Kallend D, Ray KK, et al (2020) Inclisiran for the Treatment of Heterozygous 
Familial Hypercholesterolemia. N Engl J Med; 382(16):1520-30. 
Ray KK, Stoekenbroek RM, Kallend D, et al (2019) Effect of 1 or 2 Doses of Inclisiran on 
Low-Density Lipoprotein Cholesterol Levels: One- Year Follow -up of the ORION-1 
Randomized Clinical Trial. JAMA Cardiol; 4(11):1067 -75. 
Novartis  Confidential  Page 76 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Ray KK, Wright RS, Kallend D, et al (2020) Two Phase 3 Trials of Inclisiran in Patients with 
Elevated LDL Cholesterol. N Engl J Med; 382(16):1507‐19.  
Sabatine MS, Giugliano RP, Keech AC, et al (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med; 376(18):1713-22. 
Sampson HA, Munoz-Furlong A, Bock SA, et al (2005) Symposium on the definition and 
management of anaphylaxis: summary report. J Allergy Clin Immunol; 115(3):584-91. 
Sampson HA, Munoz-Furlong A, Campbell RL, et al (2006) Second symposium on the 
definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol; 117(2):391 -7. 
Santos RD, Gidding SS, Hegele RA, et al (2016) Defining Severe Familial Hypercholesterolaemia and the Implications for Clinical Management: A Consensus Statement From the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lan cet Diabetes Endocrinol; 4:850-61. 
Santos RD, Ruzza A, Hovingh GK, et al (2020) Evolocumab in Pediatric Heterozygous Familial 
Hypercholesterolemia. N Engl J Med; 383(14):1317-27. 
Schwartz GG, Steg PG, Szarek M, et al (2018) Alirocumab and Cardiovascular Outcomes 
after Acute Coronary Syndrome. N Engl J Med; 379(22):2097-107. 
Stone NJ, Robinson JG, Lichtenstein AH, et al (2014) 2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation; 129 Supp 2:S1-S45. 
Varghese MJ (2014) Familial hypercholesterolemia: A review. Ann Pediatr Card; 7(2):107 -
17. 
WHO (2017) World Health Organization Cardiovascular diseases. (Internet) Available from: 
who.int/news- room/fact -sheets/detail/cardiovascular -diseases -(cvds) (Accessed 03 Jun 2020). 
Wiegman A, Gidding SS, Watts GF, et al (2015) Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J; 36:2425-37. 
Wilemon KA, Patel J, Aguilar-Salinas C, et al (2020) Reducing the Clinical and Public Health 
Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol; 5(2):217 -
29. 
Youngblom E, Pariani M, and Knowles JW (2016) Familial Hypercholesterolemia. Initial 
posting: January 2, 2014; last update: December 8, 2016. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 -2016. Available from: ncbi.nlm.nih.gov/books/NBK174884/ (Accessed 27 Jan 
2020). 
Novartis  Confidential  Page 77 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
16 Appendices  
16.1 Appendix 1: Diagnostic criteria for FH in adolescents / children  
Diagnosis of FH in adolescents and children according to the European Atherosclerosis 
Society Consensus Panel:  
After ruling out secondary causes of hypercholesterolemia (for example hypothyroidism, nephrotic syndrome, obstructive liver disease, obesity, anorexia nervosa and treatments such as isoretinoids), FH is diagnosed either on phenotypic criteria, i.e. elevat ed LDL -C concentration 
plus a family history of elevated LDL -C, premature coronary artery disease and/or genetic 
diagnosis, or by positive genetic testing: 
• LDL -C ≥5 mmol/L (190 mg/dL*) twice after 3 months dietary intervention: highly probably 
FH 
• LDL -C ≥4 mmol/L (160 mg/dL*) twice and family history of premature CHD in close 
relative(s) and/or high cholesterol in one parent (untreated): highly probably FH  
• LDL -C ≥3.5 mmol/L (130 mg/dL*) twice and parent has a genetic diagnosis: highly 
probably FH 
• Proven pathogenic mutation in child: definitive FH  
Source: Wiegman  et al 2015 and European Atherosclerosis Society  2015  
* Published mg/dL value by Wiegman et al 2015. Using the official conversion factor from SI 
to conventional unit for LDL- C (x 38.67): 5 mmol/L = 193 mg/dL, 4 mmol/L = 155 mg/dL, 3.5 
mmol/L = 135 mg/dL.  
Novartis  Confidential  Page 78 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
16.2 Appendix 2: Clinically notable laboratory values and vital signs  
Criteria for clinically notable vital signs are defined in Table 16-1: 
Table 16-1 Criteria for clinically notable vital signs 
Age SBP [mmHg]  DBP [mmHg]  Heart Rate [beats min-1] 
12 years*  < 90, > 130  < 50, > 80 < 50, > 105  
>12 years  < 90, > 145  < 55, > 90  < 45, > 95  
* criteria for 6 -12 years  
Criteria for clinically notable laboratory values are defined in Table 16-2 :  
Table 16-2 Clinically notable laboratory abnormalities for selected tests 
Parameter  Alert Value  
Hematology  
RBC count  >50% increase, >30% decrease  
Hemoglobin  >50% increase, >30% decrease or any value <70 g/L (<7 g/dL)  
Hematocrit  >50% increase, >30% decrease  
WBC count  >50% increase, >50% decrease  
Platelet count  >75% increase, >50% decrease  
Clinical chemistry  
Albumin  <20 g/L (<2 g/dL)  
ALT >150% increase  
AST >150% increase  
Bilirubin (Total)  >100% increase  
BUN  >50% increase  
Calcium  >10% increase, >10% decrease  
C(P)K  >300% increase  
Creatinine  >50% increase  
Chloride  >10% increase, >10% decrease  
eGFR  >30% decrease  
Glucose  >50% increase, >50% decrease, or any value <3.3 mmol/L (<60 mg/dL)  
Potassium  >20% increase, >20% decrease, or any value >5.3 mmol/L (>5.3 mEq/L)  
Sodium  >5% increase, or any value >150 mmol/L (>150 mEq/L)  
Uric acid  >50% increase  
Novartis  Confidential  Page 79 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
16.3 Appendix 3: Liver event and laboratory trigger definitions & 
follow -up requirements  
Table 16-3 Liver event and laboratory trigger definitions 
  Definition/ threshold  
Liver laboratory triggers  
If ALT, AST and total bilirubin normal at 
baseline:  • ALT or AST > 5 × ULN  
• ALP > 2 × ULN (in the absence of known bone pathology)  
• Total bilirubin > 3 × ULN (in the absence of known Gilbert 
syndrome)  
• ALT or AST > 3 × ULN and INR > 1.5 
• Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and 
Total bilirubin > 2 × ULN [mainly conjugated fraction] without 
notable increase in ALP to > 2 × ULN)  
• Any clinical event of jaundice (or equivalent term)  
• ALT or AST > 3 × ULN accompanied by (general) malaise, 
fatigue, abdominal pain, nausea, or vomiting, or rash with 
eosinophilia  
• Any adverse event potentially indicative of a liver toxicity*  
If ALT or AST abnormal at baseline:  • ALT or AST > 2x baseline or > 300 U/L (whichever occurs first)  
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related 
conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms. ULN: upper limit of 
normal  
Novartis  Confidential  Page 80 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Table 16-4 Follow up requirements for liver laboratory triggers with liver 
symptoms 
  ALT or AST  Total bilirubin  Liver Symptoms  Action  
ALT or AST increase without bilirubin increase:    
  If normal at baseline:  
ALT or AST > 3 x ULN  Normal  
For participants 
with Gilbert’s syndrome: No 
change in 
baseline total 
bilirubin  None  • No change to study 
treatment  
• Measure ALT, AST, ALP, 
GGT, total  bilirubin, direct 
and indirect bilirubin, 
PT/INR, albumin, C(P)K, and GLDH in 48-72 hours  
• Follow -up for symptoms  If elevated at baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L (whichever occurs ﬁrst) 
  If normal at baseline:  
ALT or AST > 5 x ULN for 
more than two weeks  Normal  
For participants 
with Gilbert’s 
syndrome: No 
change in 
baseline total bilirubin  None  
• Interrupt study drug  
• Measure ALT, AST, ALP, 
GGT, total  bilirubin, direct 
and indirect bilirubin, 
PT/INR, albumin, C(P)K, and GLDH in 48-72 hours  
• Follow -up for symptoms  
• Initiate close monitoring 
and workup for competing 
etiologies  
• Study drug can be 
restarted only if another 
etiology is identiﬁed and 
liver enzymes return to 
baseline  If elevated at baseline:  
ALT or AST > 3 x baseline  
or > 300 U/L (whichever 
occurs ﬁrst) for more than 
two weeks  
  If normal at baseline:  
ALT or AST > 8 x ULN  Normal  None  
ALT or AST increase with bilirubin increase:  
  If normal at baseline:  
ALT or AST > 3 x ULN  Total  bilirubin > 2 
x ULN (or INR > 
1.5) 
For participants 
with Gilbert’s 
syndrome: 
Doubling of direct 
bilirubin  None  
If elevated at baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L (whichever 
occurs ﬁrst) 
  If normal at baseline:  
ALT or AST > 3 x ULN  Normal or elevated  Severe fatigue, 
nausea, vomiting, right upper 
quadrant pain  
If elevated at baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L (whichever 
occurs ﬁrst)  
Novartis  Confidential  Page 81 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Table 16-5 Follow up requirements for liver laboratory triggers  
Criteria  Actions required  Follow -up monitoring  
Total Bilirubin (isolated)  
>1.5 – 3.0 ULN  • Maintain treatment  
• Repeat LFTs within 48-72 
hours  Monitor LFTs weekly until 
resolutiona to ≤ Grade 1 or to 
baseline  
> 3 - 10 × ULN (in the absence of 
known Gilbert syndrome)  • Interrupt treatment  
• Repeat LFT within 48-72 hours  
• Hospitalize if clinically 
appropriate  
• Establish causality  
• Record the AE and contributing 
factors (e.g. conmeds, medical history, lab) in the appropriate 
eCRF(s)  Monitor LFTs weekly until resolution
a to ≤ Grade 1 or to 
baseline (ALT, AST, total bilirubin, 
albumin, PT/INR, ALP and GGT)  
Test for hemolysis (e.g. 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)  
> 10 x ULN  • Discontinue the study treatment immediately  
• Hospitalize the participant  
• Establish causality  
• Record the AE and contributing 
factors(e.g. conmeds, medical 
history, lab) in the appropriate 
eCRF(s)  ALT, AST, total bilirubin, albumin, 
PT/INR, ALP and GGT until resolution
a (frequency at 
investigator discretion)  
Any AE potentially indicative of 
a liver toxicity  • Consider study treatment 
interruption or discontinuation  
• Hospitalization if clinically appropriate  
• Establish causality  
• Record the AE and contributing 
factors(e.g. conmeds, medical 
history, lab) in the appropriate 
eCRF(s)  Investigator discretion  
a Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at 
three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 
months, (4) liver transplantation,  and (5) death.  
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can include: Serology tests, imaging and pathology assessments, hepatologist’s consultancy; 
obtaining more detailed history of symptoms and prior or concurrent  diseases, history of 
concomitant drug use, exclusion of underlying liver disease. 
Novartis  Confidential  Page 82 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
16.4 Appendix 4: Specific Renal Alert Criteria and Actions and Event 
Follow -up 
Table 16-6 Specific renal alert criteria and actions 
Renal event  Actions  
Confirmed serum creatinine (sCr) increase 25 – 49% Consider causes and possible interventions  
Follow up within 2 -5 days  
Serum creatinine increase ≥ 50% + + OR if <18 years 
old, eGFR ≤ 35 mL/min/1.73 m2 + Consider causes and possible interventions  
Repeat assessment within 24- 48h if possible  
Consider drug interruption or discontinuation unless 
other causes are diagnosed and corrected  
Consider participant hospitalization and specialized 
treatment  
New onset dipstick proteinuria ≥ 3+  
OR 
Protein-creatinine ratio (PCR) ≥ 1g/g Cr (or mg/mmol equivalent as converted by the measuring laboratory)  Consider causes and possible interventions  
Assess serum albumin & serum total protein  
Repeat assessment to confirm  
Consider drug interruption or discontinuation unless 
other causes are diagnosed and corrected  
New onset hematuria ≥ 3+ on urine dipstick  Repeat assessment to confirm  
Distinguish hemoglobinuria from hematuria  
Urine sediment microscopy  
Assess sCr 
Exclude infection, trauma, bleeding from the distal 
urinary tract/bladder, menstruation  
Consider bleeding disorder  
+ Corresponds to KDIGO (Kidney Disease: Improving Global Outcomes) criteria for Acute Kidney Injury  
Additional specialized assessments are available to assess renal function or renal pathology. 
(Note: In exceptional cases, when a nephrologist considers a renal biopsy, it is recommended 
to make slide specimen available for evaluation by the RSG to potentially identify project -wide 
patterns of nephrotoxicity .) 
Whenever a renal event is identified, a detailed patient history and examination are indicated to identify and potentially eliminate risk factors that may have initiated or contributed to the event: 
• Blood pressure assessment (after 5 -minute rest, with an appropriate cuff size)  
• Signs and symptoms like fever, headache, shortness of breath, back or abdominal pain, 
dysuria or hematuria, dependent or periorbital edema  
• Changes in blood pressure, body weight, fluid intake, voiding pattern, or urine output 
• Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic failure, contrast media or other known nephrotoxin administration, or other diseases or causes, e.g., dehydration due to delirium, tumor lysis  
Table 16-7 Renal event follow -up 
Follow -up of renal events  
Assess, document and record in appropriate eCRF(s):  
Urine dipstick and sediment microscopy evidence of drug- induced nephrotoxicity (DIN): crystals, red blood cells 
(dysmorphic/glomerular vs. non -dysmorphic/non-glomerular), white blood cells, tubular epithelial cells  
Blood pressure and body weight  
Novartis  Confidential  Page 83 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Follow -up of renal events  
Serum creatinine, BUN, electrolytes (sodium, potassium, phosphate, calcium), bicarbonate and uric acid  
Urine output  
Review and record possible contributing factors to the renal event (co-medications, other co-morbid conditions) 
and additional diagnostic procedures (MRI etc.) in the appropriate eCRF(s)  
Monitor participant regularly (frequency at investigator’s discretion) until – 
- Event resolution: (sCr within 10% of baseline or PCR < 1 g/g Cr, or albumin-to -creatinine ratio (ACR) <300 
mg/g Cr)  
or 
- Event stabilization: sCr level with ±10% variability over last 6 months or protein-creatinine ratio stabilization at 
a new level with ±50% variability over last 6 months.  
- Analysis of urine markers in samples collected over the course of the DIN event  
Novartis  Confidential  Page 84 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
16.5 Appendix 5: Recommended Neurological Examination 
MOTOR FUNCTION 
When assessing motor function, from a neurological perspective, the assessment should focus 
on arm and leg movement. You should consider the following: 
1. Muscle size  
2. Muscle tone  
3. Muscle strength  
4. Involuntary movement  
5. Posture, gait 
Symmetry is the most important consideration when identifying focal findings. Compare one 
side of the body to the other when performing your assessment.  
Assessment of a Conscious Patient  
Limb assessment of a conscious patient usually involves a grading of strength. 
Table 16-8 Grade Strength 
Grade strength  Description  
5 Full range of motion against gravity and resistance; normal muscle strength  
4 Full range of motion against gravity and a moderate amount of resistance; slight 
weakness  
3 Full range of motion against gravity only, moderate muscle weakness  
2 Full range of motion when gravity is eliminated, severe weakness  
1 A weak muscle contraction is palpated, but no movement is noted, very severe 
weakness  
0 Complete paralysis  
NB: In a conscious patient, the single best test to quickly identify motor weakness is the “drift test”. Have the patient hold their arms outward at 90 degrees from the body. With palms up, have the patient close their eyes and hold the arms for a couple of minutes. “Drifting” will occur if one side is weak.  
Lower Extremities  
Assess the patient in a supine position. Ask him/her to separate both legs to test for hip abduction. Then ask the patient to bring the legs back together to test for hip adduction. Sit the patient on the side of the bed to assess knee flexion and extension. Ask the patient to flex and extend the knee. If able to do this, apply resistance as these movements are repeated. Test plantar and dorsiflexion by having the patient push down against your hand with their foot and then pull up against your hand with their foot. Remember to compare the left side to the right side. 
Upper Extremities  
Assess ability to flex elbow (biceps) and straighten (triceps). Assess ability to raise shoulders and return to a resting position. Assess wrist flexion and extension. Test each function with resistance. For focused upper extremity assessment, assess each digit for flexion, extension and lateral movement.  
Novartis  Confidential  Page 85 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Assessment of an Unconscious Patient  
Upper Extremities  
1. Observe the patient for spontaneous/involuntary movement. 
2. Apply painful stimuli to elicit a motor response (start with central pain; move to peripheral 
pain if no response occurs). 
3. Assess for paralysis of the limb by lifting both arms and releasing them together. If one limb 
is paralysed it will fall more rapidly than the non paralysed arm.  
Lower Extremities  
1. Observe for spontaneous/involuntary movement. 
2. Apply painful stimuli to elicit a motor response. Begin with central pain. Nailbed or peripheral pain can be attempted if the patient doesn’t respond to central pain (caution needs to be used when interpreting peripheral pain as it may stimulate spinal reflex responses vs withdrawal or other more deliberate responses).  
3. To assess for paralysis of the one limb you can position the patient on their back and flex 
the knees so that both feet are flat on the bed. Release the knees simultaneously. If the leg 
falls to an extended position with the hip externally rotated, paralysis is present. The normal leg should stay in the flexed position for a few seconds and then gradually assume its previous position. 
SENSORY FUNCTION 
When assessing sensory function remember that there are three main pathways for sensation 
and they should be compared bilaterally: 
1. Pain and temperature sensation. 
2. Position sense (proprioception).  
3. Light touch. 
Pain can be assessed using a sterile pin. Light touch can be assessed with a cotton wisp. To test 
proprioception, grasp the patient's index finger from the middle joint and move it side to side and up and down. Have the patient identify the direction of movement. Repeat this using the great toe.  
Sensory Tests:  
A number of tests for lesions of the sensory cortex can be done. Examples include the following:  
• Stereognosis:  The ability to recognize an object by feel. Place a common object in the 
persons hand and ask them to identify the object. 
• Graphesthesis:  “Draw” a number in the palm of the person’s hand and ask them to identify 
the number. 
• Two -Point Discrimination: Simultaneously apply two pin pricks to the skin surface. 
Continually repeat the test while bringing the two pins closer together, until the individual can no longer identify two separate stimuli. The finger tips are the most sensitive location for recognizing two point differences while the upper arms, thighs and back are the least sensitive.  
Novartis  Confidential  Page 86 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
• Extinction:  Touch the same spot on both sides of the body at the same time (eg, the left and 
right forearms. Ask the individual to describe how many spots are being touched. Normally, 
both sides are felt; with sensory lesions the individual will sense only one. 
• Point Locations:  Touch the surface of the skin and remove the stimulus quickly. Ask the 
individual to touch the spot where the sensation was felt. Sensory lesions can impair accurate identification, even if they retain their sensation of light touch.  
TONE and REFLEXES  
Upper motor neuron problems (brain and spinal cord) are associated with increased tone. Lower motor neuron problems are associated with decreased tone.  
Look at the muscles on each side of the body in pairs. Assess for symmetry of bulk. 
Evaluation of the stretch reflexes assesses the intactness of the spinal reflex arc at various spinal 
cord levels. The limb should be relaxed while applying a short and snappy blow with a reflex hammer. Hold the hammer loosely in a relaxed manner, making a  wrist action. Allow the 
hammer to bounce. 
Table 16-9 Reflex responses 
Reflex responses  Description  
0 No response  
1+ Diminished, low normal  
2+ Average, normal  
3+ Brisker than normal  
4+ Very brisk, hyperactive  
Lower motor neuron disease is associated with 0 or 1+, upper motor neuron disease is associated with 3+ or 
4+. 
Biceps Reflex (C5 – C6):  
Support the forearm on the examiners forearm. Place your thumb on the bicep tendon (located in the front of the bend of the elbow; midline to the anticubital fossa). Tap on your thumb to stimulate a response.  
Triceps Reflex (C7 -C8):  
Have the individual bend their elbow while pointing their arm downward at 90 degrees. Support the upper arm so that the arm hangs loosely and “goes dead”. Tap on the triceps tendon located just above the elbow bend (funny bone). 
Brachioradialis Reflex (C5 -C6):  
Hold the person’s thumb so that the forearm relaxes. Strike the forearm about 2 -3 cm above the 
radial styloid process (located along the thumb side of the wrist, about 2-3 cm above the round 
bone at the bend of the wrist). Normally, the forearm with flex and supinate. 
Quadriceps Reflex (Knee jerk) L2 – L4:  
Allow the lower legs to dangle freely. Place one hand on the quadriceps. Strike just below the 
knee cap. The lower leg normally will extend and the quadriceps will contract. 
Novartis  Confidential  Page 87 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
If the patient is supine: Stand on one side of the bed. Place the examiners forearm under the 
thigh closest to the examiner, lifting the leg up. Reach under the thigh and place the hand on the thigh of the opposite leg, just above the knee cap. Tap the kne e closest to the examiner, (the 
one that has been lifted up with the examiners forearm).  
Achilles Reflex (ankle jerks) L5 – S2:  
Flex the knee and externally rotate the hip. Dorsiflex the foot and strike the Achilles tendon of the heel. In conscious patients, kneeling on a chair can help to relax the foot. 
Heel Lift:  
While the patient is supine, bend the knee and support the leg under the thigh. Have the leg “go 
dead”. Briskly jerk the leg to lift the heel of the bed. Normally, the leg will remain relaxed and the heel will slide upward; increased tone will cause the heel and leg to stiffen and lift off the bed. 
Babinski Response:  
Dorsiflexion of the great toe with fanning of remaining toes is a positive Babinski response. 
This indicates upper motor neuron disease. It is normal in infants.  
CEREBELLAR FUNCTION  
The cerebellum is responsible for muscle coordination and balance on the same side. To test cerebellar function use the following tests:  
1. Finger to finger test: have the patient touch their index finger to your index finger (repeat several times).  
2. Finger to nose test: perform with eyes open and then eyes closed. 
3. Tandem walking: heel to toe on a straight line 
4. Romberg test: stand with feet together and arms at their sides. Have patient close his/ her eyes and maintain this position for 10 seconds. If the patient begins to sway, have them open their eyes. If swaying continues, the test is “positive” or suggestive  of cerebellum problems.  
Dizziness that occurs in response to position changes is usually blood pressure initiated. If the patient sways during a Romberg test, but stops when the eyes are opened, the problem is probably visual or CN VIII (vestibular).  
Novartis  Confidential  Page 88 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
16.6 Appendix 6: Sampson Criteria for Diagnosing Anaphylaxis  
Anaphylaxis is highly likely when any one of the following three criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips- tongue-uvula) 
AND AT LEAST ONE OF THE FOLLOWING:  
a. Respiratory compromise (eg, dyspnea, wheeze -bronchospasm, stridor, reduced peak 
expiratory flow [PEF], hypoxemia) b. Reduced blood pressure or associated symptoms of end -organ dysfunction (eg, hypotonia 
[collapse], syncope, incontinence) 2. Two or more of the following that occur rapidly after exposure to a likely allergen for that 
patient (minutes to several hours):  
a. Involvement of the skin- mucosal tissue (eg, generalized hives, itch -flush, swollen lips -
tongue-uvula) 
b. Respiratory compromise (eg, dyspnea, wheeze, bronchospasm, stridor, reduced PEF, 
hypoxemia) 
c. Reduced blood pressure or associated symptoms (eg, hypotonia [collapse], syncope, 
incontinence) 
d. Persistent gastrointestinal symptoms (eg, painful abdominal cramps, vomiting)  
3. Reduced blood pressure after exposure to a known allergen for that patient (minutes to several 
hours): 
a. Infants and children: low systolic blood pressure (age specific) or >30% decrease in systolic 
blood pressure* 
b. Adults: SBP <90 mmHg or >30% decrease from that person’s Day 1 reading *Low SBP for children is age specific and defined as: <70 mmHg from age 1 month to 1 year; 
<70 mmHg + [2 x age] for age 1 to 10 years; <90 mmHg from age 11 to 17 years. 
Source:  Sampson et al 2005 and Sampson et al 2006 
Novartis  Confidential  Page 89 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
16.7 Appendix 7: Reference table blood volume by weight  
Blood volume drawn for the purpose of this study is limited to a maximum of 2.5% of the 
circulating blood volume per sampling session and to a maximum of 5% over a 4- week period 
(Table 16 -10) (Howie  2011). Investigators may further limit the volume of blood withdrawn 
based on local institutional guidelines and if the clinical condition of the participant may be adversely affected by removal of the blood volumes stated below. Details of blood volume requir ement for  biomarker and safety samples are provided in the laboratory manual.  
Table 16-10  Reference table – blood collection volumes by body weight  
Body Weight (kg)  Total b lood volume 
(TBV) of the participant 
(mL)1 Maximum allowable 
volume (mL) in one blood draw (2.5% of 
TBV)  Total maximum volume (mL) drawn in a 28-day 
period (5% of TBV)  
20 1600  40 80 
21 1680  42 84 
22 1760  44 88 
23 1840  46 92 
24 1920  48 96 
25 2000  50 100 
26 2080  52 104 
27 2160  54 108 
28 2240  56 112 
29 2320  58 116 
30 2400  60 120 
31 2480  62 124 
32 2560  64 128 
33 2640  66 132 
34 2720  68 136 
35 2800  70 140 
36 2880  72 144 
37 2960  74 148 
38 3040  76 152 
39 3120  78 156 
40 3200  80 160 
41 3280  82 164 
42 3360  84 168 
43 3440  86 172 
44 3520  88 176 
45 3600  90 180 
46 3680  92 184 
47 3760  94 188 
48 3840  96 192 
49 3920  98 196 
50 4000  100 200 
51 4080  102 204 
52 4160  104 208 

Novartis  Confidential  Page 90 of 90 
Amended Protocol  Version 02 ( Clean )   Protocol No. CKJX839C12301  
 
Body Weight (kg)  Total b lood volume 
(TBV) of the participant 
(mL)1 Maximum allowable 
volume (mL) in one 
blood draw (2.5% of 
TBV)  Total maximum volume 
(mL) drawn in a 28-day 
period (5% of TBV)  
53 4240  106 212 
54 4320  108 216 
55 4400  110 220 
56 4480  112 224 
57 4560  114 228 
58 4640  116 232 
59 4720  118 236 
60 4800  120 240 
61 4880  122 244 
62 4960  124 248 
63 5040  126 252 
64 5120  128 256 
65 5200  130 260 
66 5280  132 264 
67 5360  134 268 
68 5440  136 272 
69 5520  138 276 
70 5600  140 280 
71 5680  142 284 
72 5760  144 288 
73 5840  146 292 
74 5920  148 296 
75 6000  150 300 
76 6080  152 304 
77 6160  154 308 
78 6240  156 312 
79 6320  158 316 
80 6400  160 320 
1: Assuming a TBV of 80 mL per kg  
For body weights not listed in the Table, use the following formulas to calculate 2.5% and 5% 
of total blood volume: 
• 2.5% of total blood volume = body weight (in kg to the closest 0.5 kg) X 2 
• 5% of total blood volume = body weight (in kg to the closest 0.5 kg) X 4 